{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T05:13:59Z","timestamp":1788671639007,"version":"build-2803163510"},"reference-count":466,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,8,31]],"date-time":"2019-08-31T00:00:00Z","timestamp":1567209600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002428","name":"Austrian Science Fund","doi-asserted-by":"publisher","award":["DK W-1206"],"award-info":[{"award-number":["DK W-1206"]}],"id":[{"id":"10.13039\/501100002428","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002428","name":"Austrian Science Fund","doi-asserted-by":"publisher","award":["SFB F4410"],"award-info":[{"award-number":["SFB F4410"]}],"id":[{"id":"10.13039\/501100002428","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002428","name":"Austrian Science Fund","doi-asserted-by":"publisher","award":["I2433-B26"],"award-info":[{"award-number":["I2433-B26"]}],"id":[{"id":"10.13039\/501100002428","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology & Therapeutics"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1016\/j.pharmthera.2019.107402","type":"journal-article","created":{"date-parts":[[2019,8,27]],"date-time":"2019-08-27T19:01:08Z","timestamp":1566932468000},"page":"107402","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":203,"special_numbering":"C","title":["Novel pharmacological targets in drug development for the treatment of anxiety and anxiety-related disorders"],"prefix":"10.1016","volume":"204","author":[{"given":"Simone B.","family":"Sartori","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Singewald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pharmthera.2019.107402_bb0005","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1111\/nyas.12718","article-title":"Ketamine as a promising prototype for a new generation of rapid-acting antidepressants","volume":"1344","author":"Abdallah","year":"2015","journal-title":"Annals of the New York Academy of Sciences"},{"key":"10.1016\/j.pharmthera.2019.107402_bb0010","article-title":"Ketamine, but not the NMDAR antagonist lanicemine, increases prefrontal global connectivity in depressed patients","volume":"2","author":"Abdallah","year":"2018","journal-title":"Chronic Stress (Thousand Oaks)"},{"key":"10.1016\/j.pharmthera.2019.107402_bb0015","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0893-133X(00)00182-2","article-title":"Dose response of arginine vasopressin to the CCK-B agonist pentagastrin","volume":"24","author":"Abelson","year":"2001","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pharmthera.2019.107402_bb0020","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.nlm.2013.11.007","article-title":"Dopamine and extinction: A convergence of theory with fear and reward circuitry","volume":"108","author":"Abraham","year":"2014","journal-title":"Neurobiology of Learning and Memory"},{"key":"10.1016\/j.pharmthera.2019.107402_bb0025","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s00213-013-3099-4","article-title":"The effect of intranasal oxytocin treatment on conditioned fear extinction and recall in a healthy human sample","volume":"229","author":"Acheson","year":"2013","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pharmthera.2019.107402_bb0030","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1002\/da.22362","article-title":"Intranasal oxytocin administration prior to exposure therapy for arachnophobia impedes treatment response","volume":"32","author":"Acheson","year":"2015","journal-title":"Depression and Anxiety"},{"key":"10.1016\/j.pharmthera.2019.107402_bb0035","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2018.7399","article-title":"Patterns in outpatient benzodiazepine prescribing in the United States","volume":"2","author":"Agarwal","year":"2019","journal-title":"JAMA Network Open"},{"key":"10.1016\/j.pharmthera.2019.107402_bb0040","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.17m11634","article-title":"Efficacy, safety, and durability of repeated ketamine infusions for comorbid posttraumatic stress disorder and treatment-resistant depression","volume":"79","author":"Albott","year":"2018","journal-title":"The Journal of Clinical Psychiatry"},{"key":"10.1016\/j.pharmthera.2019.107402_bb0045","doi-asserted-by":"crossref","first-page":"99","DOI":"10.3389\/fphar.2019.00099","article-title":"Influence of CYP2C19 metabolizer status on escitalopram\/citalopram tolerability and response in youth with anxiety and depressive disorders","volume":"10","author":"Aldrich","year":"2019","journal-title":"Frontiers in Pharmacology"},{"key":"10.1016\/j.pharmthera.2019.107402_bb0050","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1038\/s41398-017-0047-9","article-title":"A multi-dimensional characterization of anxiety in monozygotic twin pairs reveals susceptibility loci in humans","volume":"7","author":"Alisch","year":"2017","journal-title":"Translational Psychiatry"},{"key":"10.1016\/j.pharmthera.2019.107402_bb0055","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.4088\/JCP.v65n0807","article-title":"Gepirone extended-release treatment of anxious depression: Evidence from a retrospective subgroup analysis in patients with major depressive disorder","volume":"65","author":"Alpert","year":"2004","journal-title":"The Journal of Clinical Psychiatry"},{"key":"10.1016\/j.pharmthera.2019.107402_bb0060","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/0006-8993(92)91326-A","article-title":"Chronic fluoxetine treatment reduces hypothalamic vasopressin secretion in vitro","volume":"593","author":"Altemus","year":"1992","journal-title":"Brain Research"},{"key":"10.1016\/j.pharmthera.2019.107402_bb0065","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1177\/0269881116642542","article-title":"Treating posttraumatic stress disorder with MDMA-assisted psychotherapy: A preliminary meta-analysis and comparison to prolonged exposure therapy","volume":"30","author":"Amoroso","year":"2016","journal-title":"Journal of Psychopharmacology"},{"key":"10.1016\/j.pharmthera.2019.107402_bb0070","first-page":"CD006239","article-title":"Pharmacological interventions for preventing post-traumatic stress disorder (PTSD)","author":"Amos","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1016\/j.pharmthera.2019.107402_bb0075","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1097\/JCP.0b013e3181ac935c","article-title":"A randomized, double-blind, placebo-controlled trial of oral Matricaria recutita (chamomile) extract therapy for generalized anxiety disorder","volume":"29","author":"Amsterdam","year":"2009","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1016\/j.pharmthera.2019.107402_bb0080","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.ynstr.2017.03.003","article-title":"Animal models in psychiatric research: The RDoC system as a new framework for endophenotype-oriented translational neuroscience","volume":"7","author":"Anderzhanova","year":"2017","journal-title":"Neurobiology of stress"},{"key":"10.1016\/j.pharmthera.2019.107402_bb0085","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.nbd.2013.10.006","article-title":"Discovery of novel anxiolytic agents--the trials and tribulations of pre-clinical models of anxiety","volume":"61","author":"Andrews","year":"2014","journal-title":"Neurobiology of Disease"},{"key":"10.1016\/j.pharmthera.2019.107402_bb0090","doi-asserted-by":"crossref","first-page":"7874","DOI":"10.1021\/jm5006463","article-title":"Polypharmacology: Challenges and opportunities in drug discovery","volume":"57","author":"Anighoro","year":"2014","journal-title":"Journal of Medicinal Chemistry"},{"key":"10.1016\/j.pharmthera.2019.107402_bb0095","first-page":"74","article-title":"Drug and device news","volume":"43","author":"Anonymous","year":"2018","journal-title":"Pharmacy Therapeutics"},{"key":"10.1016\/j.pharmthera.2019.107402_bb0100","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1097\/FBP.0000000000000467","article-title":"Animal models of post-traumatic stress disorder and novel treatment targets","volume":"30","author":"Aspesi","year":"2019","journal-title":"Behavioural Pharmacology"},{"key":"10.1016\/j.pharmthera.2019.107402_bb0105","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S1054-3589(08)57004-9","article-title":"Subtype-selective GABA(a) receptor modulation yields a novel pharmacological profile: The design and development of TPA023","volume":"57","author":"Atack","year":"2009","journal-title":"Advances in Pharmacology"},{"key":"10.1016\/j.pharmthera.2019.107402_bb0110","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1038\/npp.2011.32","article-title":"Pregabalin influences insula and amygdala activation during anticipation of emotional images","volume":"36","author":"Aupperle","year":"2011","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pharmthera.2019.107402_bb0115","series-title":"Azevan Pharmaceuticals Reports Positive Phase 2 Exploratory Clinical Study Results with SRX246 in Intermittent Explosive Disorder","author":"Azevan","year":"2016"},{"key":"10.1016\/j.pharmthera.2019.107402_bb0120","article-title":"Pharmacological interventions for benzodiazepine discontinuation in chronic benzodiazepine users","volume":"3","author":"Baandrup","year":"2018","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1016\/j.pharmthera.2019.107402_bb0125","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/s12276-018-0063-8","article-title":"Inhibition in the amygdala anxiety circuitry","volume":"50","author":"Babaev","year":"2018","journal-title":"Experimental & Molecular Medicine"},{"key":"10.1016\/j.pharmthera.2019.107402_bb0130","doi-asserted-by":"crossref","first-page":"686","DOI":"10.2105\/AJPH.2016.303061","article-title":"Increasing benzodiazepine prescriptions and overdose mortality in the United States, 1996\u20132013","volume":"106","author":"Bachhuber","year":"2016","journal-title":"American Journal of Public Health"},{"key":"10.1016\/j.pharmthera.2019.107402_bb0135","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1177\/0269881115598411","article-title":"Efficacy and safety of pregabalin in generalised anxiety disorder: A critical review of the literature","volume":"29","author":"Baldwin","year":"2015","journal-title":"Journal of Psychopharmacology"},{"key":"10.1016\/j.pharmthera.2019.107402_bb0140","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1038\/npp.2017.272","article-title":"Single-subject anxiety treatment outcome prediction using functional neuroimaging","volume":"43","author":"Ball","year":"2018","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pharmthera.2019.107402_bb0145","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s00406-014-0563-z","article-title":"The German guidelines for the treatment of anxiety disorders","volume":"265","author":"Bandelow","year":"2015","journal-title":"European Archives of Psychiatry and Clinical Neuroscience"},{"key":"10.1016\/j.pharmthera.2019.107402_bb0150","doi-asserted-by":"crossref","first-page":"327","DOI":"10.31887\/DCNS.2015.17.3\/bbandelow","article-title":"Epidemiology of anxiety disorders in the 21st century","volume":"17","author":"Bandelow","year":"2015","journal-title":"Dialogues in Clinical Neuroscience"},{"key":"10.1016\/j.pharmthera.2019.107402_bb0155","doi-asserted-by":"crossref","first-page":"93","DOI":"10.31887\/DCNS.2017.19.2\/bbandelow","article-title":"Treatment of anxiety disorders","volume":"19","author":"Bandelow","year":"2017","journal-title":"Dialogues in Clinical Neuroscience"},{"key":"10.1016\/j.pharmthera.2019.107402_bb0160","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1097\/YIC.0000000000000078","article-title":"Efficacy of treatments for anxiety disorders: A meta-analysis","volume":"30","author":"Bandelow","year":"2015","journal-title":"International Clinical Psychopharmacology"},{"key":"10.1016\/j.pharmthera.2019.107402_bb0165","series-title":"Deutsche S3-Leitlinie Behandlung von Angstst\u00f6rungen","author":"Bandelow","year":"2014"},{"key":"10.1016\/j.pharmthera.2019.107402_bb0170","first-page":"1","article-title":"Biological markers for anxiety disorders, OCD and PTSD: A consensus statement. Part II: Neurochemistry, neurophysiology and neurocognition","author":"Bandelow","year":"2016","journal-title":"The World Journal of Biological Psychiatry"},{"key":"10.1016\/j.pharmthera.2019.107402_bb0175","doi-asserted-by":"crossref","first-page":"3206","DOI":"10.1021\/jm101459g","article-title":"Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): A novel multimodal compound for the treatment of major depressive disorder","volume":"54","author":"Bang-Andersen","year":"2011","journal-title":"Journal of Medicinal Chemistry"},{"key":"10.1016\/j.pharmthera.2019.107402_bb0180","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.adolescence.2018.08.008","article-title":"Meta-analysis of the influence of age on symptom change following cognitive-behavioural treatment for anxiety disorders","volume":"68","author":"Barry","year":"2018","journal-title":"Journal of Adolescence"},{"key":"10.1016\/j.pharmthera.2019.107402_bb0185","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/978-3-319-53889-1_8","article-title":"Anxiety and epigenetics","volume":"978","author":"Bartlett","year":"2017","journal-title":"Advances in Experimental Medicine and Biology"},{"key":"10.1016\/j.pharmthera.2019.107402_bb0190","doi-asserted-by":"crossref","first-page":"j3927","DOI":"10.1136\/bmj.j3927","article-title":"Risk of relapse after antidepressant discontinuation in anxiety disorders, obsessive-compulsive disorder, and post-traumatic stress disorder: Systematic review and meta-analysis of relapse prevention trials","volume":"358","author":"Batelaan","year":"2017","journal-title":"BMJ"},{"key":"10.1016\/j.pharmthera.2019.107402_bb0195","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/j.1755-5949.2009.00116.x","article-title":"A review of the neural mechanisms of action and clinical efficiency of riluzole in treating amyotrophic lateral sclerosis: What have we learned in the last decade?","volume":"17","author":"Bellingham","year":"2011","journal-title":"CNS Neuroscience & Therapeutics"},{"key":"10.1016\/j.pharmthera.2019.107402_bb0200","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1038\/npp.2011.6","article-title":"Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naive social phobia patients","volume":"36","author":"Bergamaschi","year":"2011","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pharmthera.2019.107402_bb0205","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.pharmthera.2017.07.002","article-title":"Pharmacology of human trace amine-associated receptors: Therapeutic opportunities and challenges","volume":"180","author":"Berry","year":"2017","journal-title":"Pharmacology & Therapeutics"},{"key":"10.1016\/j.pharmthera.2019.107402_bb0210","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1038\/npp.2009.184","article-title":"Opposite effects of delta-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology","volume":"35","author":"Bhattacharyya","year":"2010","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pharmthera.2019.107402_bb0215","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.euroneuro.2017.01.014","article-title":"The novel antipsychotic drug brexpiprazole, alone and in combination with escitalopram, facilitates prefrontal glutamatergic transmission via a dopamine D1 receptor-dependent mechanism","volume":"27","author":"Bjorkholm","year":"2017","journal-title":"European Neuropsychopharmacology"},{"key":"10.1016\/j.pharmthera.2019.107402_bb0220","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1007\/s00213-008-1354-x","article-title":"Characterization of the V1a antagonist, JNJ-17308616, in rodent models of anxiety-like behavior","volume":"202","author":"Bleickardt","year":"2009","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pharmthera.2019.107402_bb0225","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1016\/j.biopsych.2012.05.028","article-title":"Effects of ketamine in treatment-refractory obsessive-compulsive disorder","volume":"72","author":"Bloch","year":"2012","journal-title":"Biological Psychiatry"},{"key":"10.1016\/j.pharmthera.2019.107402_bb0230","series-title":"Aligning the many definitions of treatment resistance in anxiety disorders: A systematic review","author":"Bokma","year":"2019"},{"key":"10.1016\/j.pharmthera.2019.107402_bb0235","doi-asserted-by":"crossref","first-page":"13800","DOI":"10.1038\/s41598-018-32090-1","article-title":"DNA methylation in adolescents with anxiety disorder: A longitudinal study","volume":"8","author":"Bortoluzzi","year":"2018","journal-title":"Scientific Reports"},{"key":"10.1016\/j.pharmthera.2019.107402_bb0240","author":"Brennan"},{"key":"10.1016\/j.pharmthera.2019.107402_bb0245","doi-asserted-by":"crossref","first-page":"261","DOI":"10.31887\/DCNS.2015.17.3\/sbrooks","article-title":"A systematic review of the neural bases of psychotherapy for anxiety and related disorders","volume":"17","author":"Brooks","year":"2015","journal-title":"Dialogues in Clinical Neuroscience"},{"key":"10.1016\/j.pharmthera.2019.107402_bb0250","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.pscychresns.2015.06.016","article-title":"Temporal profile of brain response to alprazolam in patients with generalized anxiety disorder","volume":"233","author":"Brown","year":"2015","journal-title":"Psychiatry Research"},{"key":"10.1016\/j.pharmthera.2019.107402_bb0255","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.jpsychires.2007.05.006","article-title":"Effect of post-retrieval propranolol on psychophysiologic responding during subsequent script-driven traumatic imagery in post-traumatic stress disorder","volume":"42","author":"Brunet","year":"2008","journal-title":"Journal of Psychiatric Research"},{"key":"10.1016\/j.pharmthera.2019.107402_bb0260","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1176\/appi.ajp.2017.17050481","article-title":"Reduction of PTSD symptoms with pre-reactivation propranolol therapy: A randomized controlled trial","volume":"175","author":"Brunet","year":"2018","journal-title":"The American Journal of Psychiatry"},{"key":"10.1016\/j.pharmthera.2019.107402_bb0265","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1080\/14656566.2017.1359257","article-title":"Agomelatine for the treatment of generalized anxiety disorder","volume":"18","author":"Buoli","year":"2017","journal-title":"Expert Opinion on Pharmacotherapy"},{"key":"10.1016\/j.pharmthera.2019.107402_bb0270","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0173660","article-title":"D-cycloserine augmentation of behavior therapy for anxiety and obsessive-compulsive disorders: A meta-analysis","volume":"12","author":"Burkner","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmthera.2019.107402_bb0275","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.biopsych.2016.12.031","article-title":"Targeting the microbiota-gut-brain Axis: Prebiotics have anxiolytic and antidepressant-like effects and reverse the impact of chronic stress in mice","volume":"82","author":"Burokas","year":"2017","journal-title":"Biological Psychiatry"},{"key":"10.1016\/j.pharmthera.2019.107402_bb0280","first-page":"223","article-title":"Machine learning for precision psychiatry: Opportunities and challenges","volume":"3","author":"Bzdok","year":"2018","journal-title":"Biological Psychiatry: Cognitive Neuroscience and Neuroimaging"},{"key":"10.1016\/j.pharmthera.2019.107402_bb0285","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1038\/nn.4101","article-title":"Resolving the neural circuits of anxiety","volume":"18","author":"Calhoon","year":"2015","journal-title":"Nature Neuroscience"},{"key":"10.1016\/j.pharmthera.2019.107402_bb0290","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1097\/JCP.0000000000000180","article-title":"Use of a synthetic cannabinoid in a correctional population for posttraumatic stress disorder-related insomnia and nightmares, chronic pain, harm reduction, and other indications: A retrospective evaluation","volume":"34","author":"Cameron","year":"2014","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1016\/j.pharmthera.2019.107402_bb0295","article-title":"A 12-week double-blind, placebo-controlled, flexible-dose trial of Vilazodone in generalized social anxiety disorder","volume":"17","author":"Careri","year":"2015","journal-title":"Prim Care Companion CNS Disord"},{"key":"10.1016\/j.pharmthera.2019.107402_bb0300","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S2215-0366(16)30065-7","article-title":"Psilocybin with psychological support for treatment-resistant depression: An open-label feasibility study","volume":"3","author":"Carhart-Harris","year":"2016","journal-title":"The Lancet Psychiatry"},{"key":"10.1016\/j.pharmthera.2019.107402_bb0305","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1177\/0269881117725915","article-title":"Serotonin and brain function: A tale of two receptors","volume":"31","author":"Carhart-Harris","year":"2017","journal-title":"Journal of Psychopharmacology"},{"key":"10.1016\/j.pharmthera.2019.107402_bb0310","doi-asserted-by":"crossref","DOI":"10.1177\/2398212818774223","article-title":"The role of prefrontal-subcortical circuitry in negative bias in anxiety: Translational, developmental and treatment perspectives","volume":"2","author":"Carlisi","year":"2018","journal-title":"Brain and Neuroscience Advances"},{"key":"10.1016\/j.pharmthera.2019.107402_bb0315","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1002\/da.22728","article-title":"Cognitive behavioral therapy for anxiety and related disorders: A meta-analysis of randomized placebo-controlled trials","volume":"35","author":"Carpenter","year":"2018","journal-title":"Depression and Anxiety"},{"key":"10.1016\/j.pharmthera.2019.107402_bb0320","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.tins.2012.12.010","article-title":"Neuronal plasticity and antidepressant actions","volume":"36","author":"Castren","year":"2013","journal-title":"Trends in Neurosciences"},{"key":"10.1016\/j.pharmthera.2019.107402_bb0325","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.3000157","article-title":"Multiple functional neurosteroid binding sites on GABAA receptors","volume":"17","author":"Chen","year":"2019","journal-title":"PLoS Biology"},{"key":"10.1016\/j.pharmthera.2019.107402_bb0330","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.2147\/NDT.S164307","article-title":"Valium without dependence? Individual GABAA receptor subtype contribution toward benzodiazepine addiction, tolerance, and therapeutic effects","volume":"14","author":"Cheng","year":"2018","journal-title":"Neuropsychiatric Disease and Treatment"},{"key":"10.1016\/j.pharmthera.2019.107402_bb0335","first-page":"1","article-title":"Efficacy of vortioxetine in working patients with generalized anxiety disorder","author":"Christensen","year":"2017","journal-title":"CNS Spectrums"},{"key":"10.1016\/j.pharmthera.2019.107402_bb0340","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0157700","article-title":"Kavain, the major constituent of the anxiolytic kava extract, potentiates GABAA receptors: Functional characteristics and molecular mechanism","volume":"11","author":"Chua","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmthera.2019.107402_bb0345","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1017\/S003329171700349X","article-title":"Comparative efficacy and acceptability of pharmacological treatments for post-traumatic stress disorder in adults: A network meta-analysis","volume":"48","author":"Cipriani","year":"2018","journal-title":"Psychological Medicine"},{"key":"10.1016\/j.pharmthera.2019.107402_bb0350","article-title":"Effects of oxytocin on attention to emotional faces in healthy volunteers and highly socially anxious males","volume":"18","author":"Clark-Elford","year":"2014","journal-title":"The International Journal of Neuropsychopharmacology"},{"key":"10.1016\/j.pharmthera.2019.107402_bb0355","series-title":"30th annual psych congress. New Orleans, Louisiana","article-title":"Early improvement in somatic or psychic anxiety as a predictor of response\/remission in patients with GAD: Post hoc analysis of 3 Vilazodone studies","author":"Clayton","year":"2017"},{"key":"10.1016\/j.pharmthera.2019.107402_bb0360","doi-asserted-by":"crossref","first-page":"3738015","DOI":"10.1155\/2016\/3738015","article-title":"Neural plasticity and neurogenesis in mental disorders","volume":"2016","author":"Cocks","year":"2016","journal-title":"Neural Plasticity"},{"key":"10.1016\/j.pharmthera.2019.107402_bb0365","first-page":"521","article-title":"Consensus Guidelines on the Use of Intravenous Ketamine Infusions for Chronic Pain From the American Society of Regional Anesthesia and Pain Medicine, the American Academy of Pain Medicine, and the American Society of Anesthesiologists","volume":"43","author":"Cohen","year":"2018","journal-title":"Regional Anesthesia and Pain Medicine"},{"key":"10.1016\/j.pharmthera.2019.107402_bb0370","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1097\/00004850-200609000-00001","article-title":"Kava in generalized anxiety disorder: three placebo-controlled trials","volume":"21","author":"Connor","year":"2006","journal-title":"International Clinical Psychopharmacology"},{"key":"10.1016\/j.pharmthera.2019.107402_bb0375","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.biopsych.2005.04.043","article-title":"Riluzole augmentation in treatment-resistant obsessive-compulsive disorder: An open-label trial","volume":"58","author":"Coric","year":"2005","journal-title":"Biological Psychiatry"},{"key":"10.1016\/j.pharmthera.2019.107402_bb0380","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2018-027925","article-title":"Systematic review and meta-analysis of the association between peripheral inflammatory cytokines and generalised anxiety disorder","volume":"9","author":"Costello","year":"2019","journal-title":"BMJ Open"},{"key":"10.1016\/j.pharmthera.2019.107402_bb0385","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/fcp.12169","article-title":"Safety profile of etifoxine: A French pharmacovigilance survey","volume":"30","author":"Cottin","year":"2016","journal-title":"Fundamental & Clinical Pharmacology"},{"key":"10.1016\/j.pharmthera.2019.107402_bb0390","article-title":"Correction to 'State-of-the-art and future directions for extinction as a translational model for fear and anxiety'","volume":"373","author":"Craske","year":"2018","journal-title":"Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences"},{"key":"10.1016\/j.pharmthera.2019.107402_bb0395","doi-asserted-by":"crossref","first-page":"17100","DOI":"10.1038\/nrdp.2017.100","article-title":"Anxiety disorders","volume":"3","author":"Craske","year":"2017","journal-title":"Nature Reviews. Disease Primers"},{"key":"10.1016\/j.pharmthera.2019.107402_bb0400","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.brat.2014.04.006","article-title":"Maximizing exposure therapy: An inhibitory learning approach","volume":"58","author":"Craske","year":"2014","journal-title":"Behaviour Research and Therapy"},{"key":"10.1016\/j.pharmthera.2019.107402_bb0405","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1177\/0269881110379283","article-title":"Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: A preliminary report","volume":"25","author":"Crippa","year":"2011","journal-title":"Journal of Psychopharmacology"},{"key":"10.1016\/j.pharmthera.2019.107402_bb0410","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.3389\/fimmu.2018.02009","article-title":"Translational investigation of the therapeutic potential of Cannabidiol (CBD): Toward a new age","volume":"9","author":"Crippa","year":"2018","journal-title":"Frontiers in Immunology"},{"key":"10.1016\/j.pharmthera.2019.107402_bb0415","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1111\/jcpp.12383","article-title":"Practitioner review: Cognitive bias modification for mental health problems in children and adolescents: A meta-analysis","volume":"56","author":"Cristea","year":"2015","journal-title":"Journal of Child Psychology and Psychiatry"},{"key":"10.1016\/j.pharmthera.2019.107402_bb0420","doi-asserted-by":"crossref","first-page":"319","DOI":"10.31887\/DCNS.2015.17.3\/macrocq","article-title":"A history of anxiety: From Hippocrates to DSM","volume":"17","author":"Crocq","year":"2015","journal-title":"Dialogues in Clinical Neuroscience"},{"key":"10.1016\/j.pharmthera.2019.107402_bb0425","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1038\/nrd1825","article-title":"The ascent of mouse: Advances in modelling human depression and anxiety","volume":"4","author":"Cryan","year":"2005","journal-title":"Nature Reviews. Drug Discovery"},{"key":"10.1016\/j.pharmthera.2019.107402_bb0430","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1111\/j.1476-5381.2011.01362.x","article-title":"The age of anxiety: Role of animal models of anxiolytic action in drug discovery","volume":"164","author":"Cryan","year":"2011","journal-title":"British Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2019.107402_bb0435","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1016\/S0140-6736(18)32335-3","article-title":"Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990-2017: A systematic analysis for the Global Burden of Disease Study 2017","volume":"392","author":"DALYs GBD","year":"2018","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.pharmthera.2019.107402_bb0440","doi-asserted-by":"crossref","first-page":"3137","DOI":"10.1007\/s00213-018-5010-9","article-title":"Reduction in social anxiety after MDMA-assisted psychotherapy with autistic adults: A randomized, double-blind, placebo-controlled pilot study","volume":"235","author":"Danforth","year":"2018","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pharmthera.2019.107402_bb0445","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.pnpbp.2015.03.011","article-title":"MDMA-assisted therapy: A new treatment model for social anxiety in autistic adults","volume":"64","author":"Danforth","year":"2016","journal-title":"Progress in Neuro-Psychopharmacology & Biological Psychiatry"},{"key":"10.1016\/j.pharmthera.2019.107402_bb0450","series-title":"Challenges and opportunities in central nervous system drug discovery","author":"Danon","year":"2019"},{"key":"10.1016\/j.pharmthera.2019.107402_bb0455","unstructured":"Daugherty B, Sullivan G, Gershell L, Lederman S (2015) Serotonin receptor profiles of bedtime pharmacotherapies targeting posttraumatic stress disorder (PTSD) Biological Psychiatry 77(Supplement):271S-272S."},{"key":"10.1016\/j.pharmthera.2019.107402_bb0460","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.3390\/ijms16011111","article-title":"Agomelatine beyond borders: Current evidences of its efficacy in disorders other than major depression","volume":"16","author":"De Berardis","year":"2015","journal-title":"International Journal of Molecular Sciences"},{"key":"10.1016\/j.pharmthera.2019.107402_bb0465","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/YCO.0000000000000468","article-title":"Predicting treatment outcome for anxiety disorders with or without comorbid depression using clinical, imaging and (epi)genetic data","volume":"32","author":"Deckert","year":"2019","journal-title":"Current Opinion in Psychiatry"},{"issue":"7","key":"10.1016\/j.pharmthera.2019.107402_bb0470","doi-asserted-by":"crossref","first-page":"3101","DOI":"10.1021\/acschemneuro.8b00661","article-title":"Serotonin 5-HT1A receptor biased agonists display differential anxiolytic activity in a rat social interaction model","volume":"10","author":"Depoortere","year":"2019","journal-title":"ACS Chemical Neuroscience"},{"key":"10.1016\/j.pharmthera.2019.107402_bb0475","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.conb.2013.01.013","article-title":"Towards new approaches to disorders of fear and anxiety","volume":"23","author":"Dias","year":"2013","journal-title":"Current Opinion in Neurobiology"},{"key":"10.1016\/j.pharmthera.2019.107402_bb0480","doi-asserted-by":"crossref","first-page":"303","DOI":"10.3390\/metabo2020303","article-title":"A historical overview of natural products in drug discovery","volume":"2","author":"Dias","year":"2012","journal-title":"Metabolites"},{"key":"10.1016\/j.pharmthera.2019.107402_bb0485","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1186\/s12967-017-1237-1","article-title":"Xenon in the treatment of panic disorder: An open label study","volume":"15","author":"Dobrovolsky","year":"2017","journal-title":"Journal of Translational Medicine"},{"key":"10.1016\/j.pharmthera.2019.107402_bb0490","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1038\/npp.2014.53","article-title":"Modulation of resting-state amygdala-frontal functional connectivity by oxytocin in generalized social anxiety disorder","volume":"39","author":"Dodhia","year":"2014","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pharmthera.2019.107402_bb0495","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.pscychresns.2016.04.009","article-title":"Resting functional connectivity in social anxiety disorder and the effect of pharmacotherapy","volume":"251","author":"Doruyter","year":"2016","journal-title":"Psychiatry Research: Neuroimaging"},{"key":"10.1016\/j.pharmthera.2019.107402_bb0500","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1080\/17512433.2018.1511424","article-title":"Efficacy, tolerability, and safety of serotonergic psychedelics for the management of mood, anxiety, and substance-use disorders: A systematic review of systematic reviews","volume":"11","author":"Dos Santos","year":"2018","journal-title":"Expert Review of Clinical Pharmacology"},{"key":"10.1016\/j.pharmthera.2019.107402_bb0505","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1016\/j.euroneuro.2016.03.006","article-title":"Comparing the actions of lanicemine and ketamine in depression: Key role of the anterior cingulate","volume":"26","author":"Downey","year":"2016","journal-title":"European Neuropsychopharmacology"},{"key":"10.1016\/j.pharmthera.2019.107402_bb0510","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1113\/jphysiol.2006.124958","article-title":"Subunit-specific mechanisms and proton sensitivity of NMDA receptor channel block","volume":"581","author":"Dravid","year":"2007","journal-title":"Journal of Physiology"},{"key":"10.1016\/j.pharmthera.2019.107402_bb0515","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/j.biopsych.2017.06.024","article-title":"Corticotropin-releasing Factor receptor 1 antagonism is ineffective for women with posttraumatic stress disorder","volume":"82","author":"Dunlop","year":"2017","journal-title":"Biological Psychiatry"},{"key":"10.1016\/j.pharmthera.2019.107402_bb0520","first-page":"115","article-title":"Neural circuits in anxiety and stress disorders: A focused review","volume":"11","author":"Duval","year":"2015","journal-title":"Therapeutics and Clinical Risk Management"},{"key":"10.1016\/j.pharmthera.2019.107402_bb0525","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.2174\/138161209788168074","article-title":"Tachykinin receptors as therapeutic targets in stress-related disorders","volume":"15","author":"Ebner","year":"2009","journal-title":"Current Pharmaceutical Design"},{"key":"10.1016\/j.pharmthera.2019.107402_bb0530","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.biopsych.2014.10.015","article-title":"Oxytocin facilitates the extinction of conditioned fear in humans","volume":"78","author":"Eckstein","year":"2015","journal-title":"Biological Psychiatry"},{"key":"10.1016\/j.pharmthera.2019.107402_bb0535","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.tips.2018.04.003","article-title":"An emerging circuit pharmacology of GABAA receptors","volume":"39","author":"Engin","year":"2018","journal-title":"Trends in Pharmacological Sciences"},{"key":"10.1016\/j.pharmthera.2019.107402_bb0540","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1126\/science.aaf7497","article-title":"Activity-based protein profiling reveals off-target proteins of the FAAH inhibitor BIA 10-2474","volume":"356","author":"van Esbroeck","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.pharmthera.2019.107402_bb0545","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1176\/appi.ajp.2007.07030504","article-title":"Functional neuroimaging of anxiety: A meta-analysis of emotional processing in PTSD, social anxiety disorder, and specific phobia","volume":"164","author":"Etkin","year":"2007","journal-title":"The American Journal of Psychiatry"},{"key":"10.1016\/j.pharmthera.2019.107402_bb0550","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aal3236","article-title":"Using fMRI connectivity to define a treatment-resistant form of post-traumatic stress disorder","volume":"11","author":"Etkin","year":"2019","journal-title":"Science Translational Medicine"},{"key":"10.1016\/j.pharmthera.2019.107402_bb0555","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/j.sapharm.2018.06.018","article-title":"Reports of gabapentin and pregabalin abuse, misuse, dependence, or overdose: An analysis of the food and drug administration adverse events reporting system (FAERS)","volume":"15","author":"Evoy","year":"2019","journal-title":"Research in Social & Administrative Pharmacy"},{"key":"10.1016\/j.pharmthera.2019.107402_bb0560","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1002\/jps.23495","article-title":"Pharmacokinetics and metabolism of SRX246: a potent and selective vasopressin 1a antagonist","volume":"102","author":"Fabio","year":"2013","journal-title":"Journal of Pharmaceutical Sciences"},{"key":"10.1016\/j.pharmthera.2019.107402_bb0565","author":"Fabre-Kramer"},{"key":"10.1016\/j.pharmthera.2019.107402_bb0570","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.biopsycho.2017.05.015","article-title":"Working hard for oneself or others: Effects of oxytocin on reward motivation in social anxiety disorder","volume":"127","author":"Fang","year":"2017","journal-title":"Biological Psychology"},{"key":"10.1016\/j.pharmthera.2019.107402_bb0575","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1124\/pr.114.009126","article-title":"Targeting the modulation of neural circuitry for the treatment of anxiety disorders","volume":"66","author":"Farb","year":"2014","journal-title":"Pharmacological Reviews"},{"key":"10.1016\/j.pharmthera.2019.107402_bb0580","author":"FDA"},{"key":"10.1016\/j.pharmthera.2019.107402_bb0585","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1001\/jamapsychiatry.2014.62","article-title":"Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: A randomized clinical trial","volume":"71","author":"Feder","year":"2014","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.pharmthera.2019.107402_bb0590","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1080\/10715762.2018.1475733","article-title":"The role of oxidative stress in anxiety disorder: Cause or consequence?","volume":"52","author":"Fedoce","year":"2018","journal-title":"Free Radical Research"},{"key":"10.1016\/j.pharmthera.2019.107402_bb0595","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.biopha.2017.08.107","article-title":"Therapeutical strategies for anxiety and anxiety-like disorders using plant-derived natural compounds and plant extracts","volume":"95","author":"Fedotova","year":"2017","journal-title":"Biomedicine & Pharmacotherapy"},{"key":"10.1016\/j.pharmthera.2019.107402_bb0600","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1007\/s00213-017-4779-2","article-title":"Progress and promise for the MDMA drug development program","volume":"235","author":"Feduccia","year":"2018","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pharmthera.2019.107402_bb0605","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.pnpbp.2018.03.003","article-title":"MDMA-assisted psychotherapy for PTSD: Are memory reconsolidation and fear extinction underlying mechanisms?","volume":"84","author":"Feduccia","year":"2018","journal-title":"Progress in Neuro-Psychopharmacology & Biological Psychiatry"},{"key":"10.1016\/j.pharmthera.2019.107402_bb0610","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1002\/da.22735","article-title":"Clinical and functional outcomes of cannabis use among individuals with anxiety disorders: A 3-year population-based longitudinal study","volume":"35","author":"Feingold","year":"2018","journal-title":"Depression and Anxiety"},{"key":"10.1016\/j.pharmthera.2019.107402_bb0615","doi-asserted-by":"crossref","first-page":"533","DOI":"10.2174\/1570159X15666171123201142","article-title":"Imaging the role of inflammation in mood and anxiety-related disorders","volume":"16","author":"Felger","year":"2018","journal-title":"Current Neuropharmacology"},{"key":"10.1016\/j.pharmthera.2019.107402_bb0620","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/s41583-018-0039-7","article-title":"Brain circuit dysfunction in post-traumatic stress disorder: From mouse to man","volume":"19","author":"Fenster","year":"2018","journal-title":"Nature Reviews. Neuroscience"},{"key":"10.1016\/j.pharmthera.2019.107402_bb0625","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.coph.2018.02.004","article-title":"Metabotropic glutamate receptors as targets for novel anxiolytics","volume":"38","author":"Ferraguti","year":"2018","journal-title":"Current Opinion in Pharmacology"},{"key":"10.1016\/j.pharmthera.2019.107402_bb0630","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.jpsychires.2017.12.014","article-title":"Augmenting prolonged exposure therapy for PTSD with intranasal oxytocin: A randomized, placebo-controlled pilot trial","volume":"98","author":"Flanagan","year":"2018","journal-title":"Journal of Psychiatric Research"},{"key":"10.1016\/j.pharmthera.2019.107402_bb0635","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s12888-019-2022-x","article-title":"Cannabidiol enhancement of exposure therapy in treatment refractory patients with phobias: Study protocol of a randomized controlled trial","volume":"19","author":"van der Flier","year":"2019","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.pharmthera.2019.107402_bb0640","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1038\/s41380-017-0006-0","article-title":"Lost in translation: How to upgrade fear memory research","volume":"23","author":"Flores","year":"2018","journal-title":"Molecular Psychiatry"},{"key":"10.1016\/j.pharmthera.2019.107402_bb0645","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.tins.2015.06.005","article-title":"Orexins and fear: Implications for the treatment of anxiety disorders","volume":"38","author":"Flores","year":"2015","journal-title":"Trends in Neurosciences"},{"key":"10.1016\/j.pharmthera.2019.107402_bb0650","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.neuropharm.2018.05.009","article-title":"Ketamine facilitates extinction of avoidance behavior and enhances synaptic plasticity in a rat model of anxiety vulnerability: Implications for the pathophysiology and treatment of anxiety disorders","volume":"137","author":"Fortress","year":"2018","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pharmthera.2019.107402_bb0655","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1176\/appi.ajp.2014.14040449","article-title":"A translational neuroscience approach to understanding the development of social anxiety disorder and its pathophysiology","volume":"171","author":"Fox","year":"2014","journal-title":"The American Journal of Psychiatry"},{"key":"10.1016\/j.pharmthera.2019.107402_bb0660","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1080\/17460441.2018.1418321","article-title":"Challenges with modelling anxiety disorders: A possible hindrance for drug discovery","volume":"13","author":"Freudenberg","year":"2018","journal-title":"Expert Opinion on Drug Discovery"},{"key":"10.1016\/j.pharmthera.2019.107402_bb0665","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1192\/bjo.2018.15","article-title":"Anterior cingulate cortex activity as a candidate biomarker for treatment selection in social anxiety disorder","volume":"4","author":"Frick","year":"2018","journal-title":"BJPsych Open"},{"key":"10.1016\/j.pharmthera.2019.107402_bb0670","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1093\/ijnp\/pyx116","article-title":"Role of 5-HT1A receptor stimulation in the medial prefrontal cortex in the sustained antidepressant effects of ketamine","volume":"21","author":"Fukumoto","year":"2018","journal-title":"The International Journal of Neuropsychopharmacology"},{"key":"10.1016\/j.pharmthera.2019.107402_bb0675","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.psychres.2015.05.036","article-title":"Neuroinflammatory pathways in anxiety, posttraumatic stress, and obsessive compulsive disorders","volume":"229","author":"Furtado","year":"2015","journal-title":"Psychiatry Research"},{"key":"10.1016\/j.pharmthera.2019.107402_bb0680","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.14137","article-title":"Cyclooxygenase-2 inhibition reduces stress-induced affective pathology","volume":"5","author":"Gamble-George","year":"2016","journal-title":"Elife"},{"key":"10.1016\/j.pharmthera.2019.107402_bb0685","doi-asserted-by":"crossref","first-page":"7650","DOI":"10.1073\/pnas.1602620113","article-title":"Oxytocin, the peptide that bonds the sexes also divides them","volume":"113","author":"Gao","year":"2016","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.pharmthera.2019.107402_bb0690","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1007\/s00213-013-3389-x","article-title":"5-HT(1A) [corrected] receptors in mood and anxiety: Recent insights into autoreceptor versus heteroreceptor function","volume":"231","author":"Garcia-Garcia","year":"2014","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pharmthera.2019.107402_bb0695","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1038\/s41398-017-0016-3","article-title":"The role of anxious distress in immune dysregulation in patients with major depressive disorder","volume":"7","author":"Gaspersz","year":"2017","journal-title":"Translational Psychiatry"},{"key":"10.1016\/j.pharmthera.2019.107402_bb0700","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1038\/s41398-019-0506-6","article-title":"Differences between ketamine's short-term and long-term effects on brain circuitry in depression","volume":"9","author":"Gass","year":"2019","journal-title":"Translational Psychiatry"},{"key":"10.1016\/j.pharmthera.2019.107402_bb0705","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1177\/0269881114555249","article-title":"LSD-assisted psychotherapy for anxiety associated with a life-threatening disease: A qualitative study of acute and sustained subjective effects","volume":"29","author":"Gasser","year":"2015","journal-title":"Journal of Psychopharmacology"},{"key":"10.1016\/j.pharmthera.2019.107402_bb0710","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1078\/0944-7113-00369","article-title":"Treatment of anxiety, tension and restlessness states with Kava special extract WS 1490 in general practice: A randomized placebo-controlled double-blind multicenter trial","volume":"10","author":"Gastpar","year":"2003","journal-title":"Phytomedicine"},{"key":"10.1016\/j.pharmthera.2019.107402_bb0715","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/YIC.0000000000000147","article-title":"Pregabalin for generalized anxiety disorder: An updated systematic review and meta-analysis","volume":"32","author":"Generoso","year":"2017","journal-title":"International Clinical Psychopharmacology"},{"key":"10.1016\/j.pharmthera.2019.107402_bb0720","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1037\/adb0000154","article-title":"Prevalence and correlates of cannabis use in an outpatient VA posttraumatic stress disorder clinic","volume":"30","author":"Gentes","year":"2016","journal-title":"Psychology of Addictive Behaviors"},{"key":"10.1016\/j.pharmthera.2019.107402_bb0725","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.drudis.2016.01.016","article-title":"Emerging treatment mechanisms for depression: Focus on glutamate and synaptic plasticity","volume":"21","author":"Gerhard","year":"2016","journal-title":"Drug Discovery Today"},{"key":"10.1016\/j.pharmthera.2019.107402_bb0730","doi-asserted-by":"crossref","first-page":"4294","DOI":"10.1038\/s41467-018-06785-y","article-title":"Dopamine-dependent prefrontal reactivations explain long-term benefit of fear extinction","volume":"9","author":"Gerlicher","year":"2018","journal-title":"Nature Communications"},{"key":"10.1016\/j.pharmthera.2019.107402_bb0735","doi-asserted-by":"crossref","DOI":"10.1007\/s00213-019-05301-4","article-title":"L-DOPA improves extinction memory retrieval after successful fear extinction","author":"Gerlicher","year":"2019","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pharmthera.2019.107402_bb0740","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.euroneuro.2013.09.004","article-title":"Functional effects of chronic paroxetine versus placebo on the fear, stress and anxiety brain circuit in social anxiety disorder: Initial validation of an imaging protocol for drug discovery","volume":"24","author":"Gimenez","year":"2014","journal-title":"European Neuropsychopharmacology"},{"key":"10.1016\/j.pharmthera.2019.107402_bb0745","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1177\/0269881117705089","article-title":"Ketamine's dose-related effects on anxiety symptoms in patients with treatment refractory anxiety disorders","volume":"31","author":"Glue","year":"2017","journal-title":"Journal of Psychopharmacology"},{"key":"10.1016\/j.pharmthera.2019.107402_bb0750","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1177\/0269881118762073","article-title":"Safety and efficacy of maintenance ketamine treatment in patients with treatment-refractory generalised anxiety and social anxiety disorders","volume":"32","author":"Glue","year":"2018","journal-title":"Journal of Psychopharmacology"},{"key":"10.1016\/j.pharmthera.2019.107402_bb0755","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1080\/14656566.2018.1472767","article-title":"Comparing the efficacy of benzodiazepines and serotonergic anti-depressants for adults with generalized anxiety disorder: A meta-analytic review","volume":"19","author":"Gomez","year":"2018","journal-title":"Expert Opinion on Pharmacotherapy"},{"key":"10.1016\/j.pharmthera.2019.107402_bb0760","doi-asserted-by":"crossref","first-page":"138","DOI":"10.3389\/fncel.2019.00138","article-title":"Effects of different stressors are modulated by different neurobiological systems: The role of GABA-A versus CB1 receptor gene variants in anxiety and depression","volume":"13","author":"Gonda","year":"2019","journal-title":"Frontiers in Cellular Neuroscience"},{"key":"10.1016\/j.pharmthera.2019.107402_bb0765","series-title":"Charney & Nestler's neurobiology of mental illness","first-page":"435","article-title":"Functional Neurocircuitry and neuroimaging studies of anxiety disorders","author":"Goodkind","year":"2018"},{"key":"10.1016\/j.pharmthera.2019.107402_bb0770","doi-asserted-by":"crossref","first-page":"159","DOI":"10.31887\/DCNS.2017.19.2\/kdomschke","article-title":"Genetics of generalized anxiety disorder and related traits","volume":"19","author":"Gottschalk","year":"2017","journal-title":"Dialogues in Clinical Neuroscience"},{"key":"10.1016\/j.pharmthera.2019.107402_bb0775","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/7854_2017_25","article-title":"Oxytocin and anxiety disorders","volume":"35","author":"Gottschalk","year":"2018","journal-title":"Current Topics in Behavioral Neurosciences"},{"key":"10.1016\/j.pharmthera.2019.107402_bb0780","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.cell.2013.12.020","article-title":"Epigenetic priming of memory updating during reconsolidation to attenuate remote fear memories","volume":"156","author":"Graff","year":"2014","journal-title":"Cell"},{"key":"10.1016\/j.pharmthera.2019.107402_bb0785","series-title":"Latest Advances in Psychiatry Symposium. London","article-title":"Treating generalised anxiety disorder: Room to improve","author":"Greener","year":"2009"},{"key":"10.1016\/j.pharmthera.2019.107402_bb0790","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1038\/nrd4075","article-title":"50 years of hurdles and hope in anxiolytic drug discovery","volume":"12","author":"Griebel","year":"2013","journal-title":"Nature Reviews. Drug Discovery"},{"key":"10.1016\/j.pharmthera.2019.107402_bb0795","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1038\/nrd3702","article-title":"Neuropeptide receptor ligands as drugs for psychiatric diseases: The end of the beginning?","volume":"11","author":"Griebel","year":"2012","journal-title":"Nature Reviews. Drug Discovery"},{"key":"10.1016\/j.pharmthera.2019.107402_bb0800","article-title":"Central amygdala circuit dynamics underlying the benzodiazepine anxiolytic effect","author":"Griessner","year":"2018","journal-title":"Molecular Psychiatry"},{"key":"10.1016\/j.pharmthera.2019.107402_bb0805","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1177\/0269881116675513","article-title":"Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial","volume":"30","author":"Griffiths","year":"2016","journal-title":"Journal of Psychopharmacology"},{"key":"10.1016\/j.pharmthera.2019.107402_bb0810","doi-asserted-by":"crossref","DOI":"10.1038\/s41386-019-0445-1","article-title":"Modeling anxiety in healthy humans: A key intermediate bridge between basic and clinical sciences","author":"Grillon","year":"2019","journal-title":"Neuropsychopharmacology."},{"key":"10.1016\/j.pharmthera.2019.107402_bb0815","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.euroneuro.2018.03.016","article-title":"Psilocybin modulates functional connectivity of the amygdala during emotional face discrimination","volume":"28","author":"Grimm","year":"2018","journal-title":"European Neuropsychopharmacology"},{"key":"10.1016\/j.pharmthera.2019.107402_bb0820","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1037\/adb0000109","article-title":"Can marijuana make it better? Prospective effects of marijuana and temperament on risk for anxiety and depression","volume":"29","author":"Grunberg","year":"2015","journal-title":"Psychology of Addictive Behaviors"},{"key":"10.1016\/j.pharmthera.2019.107402_bb0825","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s00441-018-2902-2","article-title":"Brain neuropeptide S: Via GPCR activation to a powerful neuromodulator of socio-emotional behaviors","volume":"375","author":"Grund","year":"2019","journal-title":"Cell and Tissue Research"},{"key":"10.1016\/j.pharmthera.2019.107402_bb0830","doi-asserted-by":"crossref","first-page":"3604","DOI":"10.1111\/bph.12720","article-title":"Agomelatine: Mechanism of action and pharmacological profile in relation to antidepressant properties","volume":"171","author":"Guardiola-Lemaitre","year":"2014","journal-title":"British Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2019.107402_bb0835","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/j.psyneuen.2009.01.005","article-title":"A randomized controlled trial of intranasal oxytocin as an adjunct to exposure therapy for social anxiety disorder","volume":"34","author":"Guastella","year":"2009","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.pharmthera.2019.107402_bb0840","series-title":"Charney & Nestler's neurobiology of mental illness","article-title":"Current and experimental treatments for anxiety disorders","author":"Guastella","year":"2018"},{"key":"10.1016\/j.pharmthera.2019.107402_bb0845","doi-asserted-by":"crossref","DOI":"10.3390\/jcm7020017","article-title":"Benzodiazepines I: Upping the care on downers: The evidence of risks, benefits and alternatives","volume":"7","author":"Guina","year":"2018","journal-title":"Journal of Clinical Medicine"},{"key":"10.1016\/j.pharmthera.2019.107402_bb0850","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.tips.2013.08.008","article-title":"Amygdala FAAH and anandamide: Mediating protection and recovery from stress","volume":"34","author":"Gunduz-Cinar","year":"2013","journal-title":"Trends in Pharmacological Sciences"},{"key":"10.1016\/j.pharmthera.2019.107402_bb0855","first-page":"E2428","article-title":"Single dose of L-dopa makes extinction memories context-independent and prevents the return of fear","volume":"110","author":"Haaker","year":"2013","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.pharmthera.2019.107402_bb0860","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1177\/0269881106072343","article-title":"Pharmacodynamic and pharmacokinetic effects of TPA023, a GABA(A) alpha(2,3) subtype-selective agonist, compared to lorazepam and placebo in healthy volunteers","volume":"21","author":"de Haas","year":"2007","journal-title":"Journal of Psychopharmacology"},{"key":"10.1016\/j.pharmthera.2019.107402_bb0865","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.physbeh.2018.12.007","article-title":"3,4-methylenedioxymethamphetamine (MDMA) impairs the extinction and reconsolidation of fear memory in rats","volume":"199","author":"Hake","year":"2019","journal-title":"Physiology & Behavior"},{"key":"10.1016\/j.pharmthera.2019.107402_bb0870","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1016\/j.neubiorev.2012.09.001","article-title":"Classical and novel approaches to the preclinical testing of anxiolytics: A critical evaluation","volume":"37","author":"Haller","year":"2013","journal-title":"Neuroscience and Biobehavioral Reviews"},{"key":"10.1016\/j.pharmthera.2019.107402_bb0875","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1002\/ptr.4677","article-title":"The anxiolytic potential and psychotropic side effects of an echinacea preparation in laboratory animals and healthy volunteers","volume":"27","author":"Haller","year":"2013","journal-title":"Phytotherapy Research"},{"key":"10.1016\/j.pharmthera.2019.107402_bb0880","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.bbr.2017.10.016","article-title":"Animals, anxiety, and anxiety disorders: How to measure anxiety in rodents and why","volume":"352","author":"Harro","year":"2018","journal-title":"Behavioural Brain Research"},{"key":"10.1016\/j.pharmthera.2019.107402_bb0885","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1101\/lm.1682410","article-title":"Systemic or intra-amygdala infusion of the benzodiazepine, midazolam, impairs learning, but facilitates re-learning to inhibit fear responses in extinction","volume":"17","author":"Hart","year":"2010","journal-title":"Learning & Memory"},{"key":"10.1016\/j.pharmthera.2019.107402_bb0890","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s00213-017-4786-3","article-title":"Impact of oral ketamine augmentation on hospital admissions in treatment-resistant depression and PTSD: A retrospective study","volume":"235","author":"Hartberg","year":"2018","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pharmthera.2019.107402_bb0895","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1097\/ALN.0b013e31818d6aee","article-title":"Xenon reduces N-methyl-D-aspartate and alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor-mediated synaptic transmission in the amygdala","volume":"109","author":"Haseneder","year":"2008","journal-title":"Anesthesiology"},{"key":"10.1016\/j.pharmthera.2019.107402_bb0900","doi-asserted-by":"crossref","first-page":"120","DOI":"10.2174\/1570159X11666131120232135","article-title":"Association of oxidative stress to the genesis of anxiety: Implications for possible therapeutic interventions","volume":"12","author":"Hassan","year":"2014","journal-title":"Current Neuropharmacology"},{"key":"10.1016\/j.pharmthera.2019.107402_bb0905","series-title":"Current Topics in Behavioral Neurosciences","doi-asserted-by":"crossref","DOI":"10.1007\/7854_2018_63","article-title":"The impact of stressor exposure and glucocorticoids on anxiety and fear","author":"Hassell","year":"2018"},{"key":"10.1016\/j.pharmthera.2019.107402_bb0910","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0062741","article-title":"Plasma concentrations of endocannabinoids and related primary fatty acid amides in patients with post-traumatic stress disorder","volume":"8","author":"Hauer","year":"2013","journal-title":"PLoS One"},{"issue":"34","key":"10.1016\/j.pharmthera.2019.107402_bb0915","doi-asserted-by":"crossref","first-page":"4051","DOI":"10.2174\/1381612824666181120094749","article-title":"Synaptic plasticity in PTSD and associated comorbidities: The function and mechanism for diagnostics and therapy","volume":"24","author":"He","year":"2018","journal-title":"Current Pharmaceutical Design"},{"key":"10.1016\/j.pharmthera.2019.107402_bb0920","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.biopsych.2016.05.012","article-title":"Circuit-based Corticostriatal homologies between rat and primate","volume":"80","author":"Heilbronner","year":"2016","journal-title":"Biological Psychiatry"},{"key":"10.1016\/j.pharmthera.2019.107402_bb0925","doi-asserted-by":"crossref","first-page":"541","DOI":"10.2217\/pgs.15.15","article-title":"Serotonin pathway polymorphisms and the treatment of major depressive disorder and anxiety disorders","volume":"16","author":"Helton","year":"2015","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.pharmthera.2019.107402_bb0930","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.nlm.2017.01.007","article-title":"Reconsolidation and extinction: Using epigenetic signatures to challenge conventional wisdom","volume":"142","author":"Hemstedt","year":"2017","journal-title":"Neurobiology of Learning and Memory"},{"key":"10.1016\/j.pharmthera.2019.107402_bb0935","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.expneurol.2016.05.014","article-title":"Noradrenergic dysregulation in the pathophysiology of PTSD","volume":"284","author":"Hendrickson","year":"2016","journal-title":"Experimental Neurology"},{"key":"10.1016\/j.pharmthera.2019.107402_bb0940","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1038\/nn.3480","article-title":"Substrate-selective COX-2 inhibition decreases anxiety via endocannabinoid activation","volume":"16","author":"Hermanson","year":"2013","journal-title":"Nature Neuroscience"},{"key":"10.1016\/j.pharmthera.2019.107402_bb0945","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1055\/s-2007-981539","article-title":"Efficacy and tolerability of a standardized herbal product from Galphimia glauca on generalized anxiety disorder. A randomized, double-blind clinical trial controlled with lorazepam","volume":"73","author":"Herrera-Arellano","year":"2007","journal-title":"Planta Medica"},{"key":"10.1016\/j.pharmthera.2019.107402_bb0950","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1001\/archpsyc.62.2.182","article-title":"The structure of genetic and environmental risk factors for anxiety disorders in men and women","volume":"62","author":"Hettema","year":"2005","journal-title":"Archives of General Psychiatry"},{"key":"10.1016\/j.pharmthera.2019.107402_bb0955","doi-asserted-by":"crossref","first-page":"2952","DOI":"10.1016\/j.psyneuen.2013.08.004","article-title":"Reductions in circulating endocannabinoid levels in individuals with post-traumatic stress disorder following exposure to the World Trade Center attacks","volume":"38","author":"Hill","year":"2013","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.pharmthera.2019.107402_bb0960","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1016\/j.psyneuen.2009.03.013","article-title":"Circulating endocannabinoids and N-acyl ethanolamines are differentially regulated in major depression and following exposure to social stress","volume":"34","author":"Hill","year":"2009","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.pharmthera.2019.107402_bb0965","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1055\/s-2007-993211","article-title":"Serum endocannabinoid content is altered in females with depressive disorders: A preliminary report","volume":"41","author":"Hill","year":"2008","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.pharmthera.2019.107402_bb0970","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1037\/tra0000180","article-title":"Meditation for posttraumatic stress: Systematic review and meta-analysis","volume":"9","author":"Hilton","year":"2017","journal-title":"Psychological Trauma"},{"key":"10.1016\/j.pharmthera.2019.107402_bb0975","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.ejphar.2014.02.027","article-title":"Characterization of a novel vasopressin V1b receptor antagonist, V1B-30N, in animal models of anxiety-like and depression-like behavior","volume":"730","author":"Hodgson","year":"2014","journal-title":"European Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2019.107402_bb0980","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1007\/s11920-014-0532-2","article-title":"D-cycloserine augmentation of cognitive behavioral therapy for anxiety disorders: An update","volume":"17","author":"Hofmann","year":"2015","journal-title":"Current Psychiatry Reports"},{"key":"10.1016\/j.pharmthera.2019.107402_bb0985","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/j.1755-5949.2010.00227.x","article-title":"Effect of acute posttrauma propranolol on PTSD outcome and physiological responses during script-driven imagery","volume":"18","author":"Hoge","year":"2012","journal-title":"CNS Neuroscience & Therapeutics"},{"key":"10.1016\/j.pharmthera.2019.107402_bb0990","doi-asserted-by":"crossref","first-page":"106","DOI":"10.3389\/fncir.2018.00106","article-title":"Neuropeptide and small transmitter coexistence: Fundamental studies and relevance to mental illness","volume":"12","author":"H\u00f6kfelt","year":"2018","journal-title":"Front Neural Circuits"},{"key":"10.1016\/j.pharmthera.2019.107402_bb0995","doi-asserted-by":"crossref","first-page":"15486","DOI":"10.1073\/pnas.1512653112","article-title":"Mitochondrial function in the brain links anxiety with social subordination","volume":"112","author":"Hollis","year":"2015","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.pharmthera.2019.107402_bb1000","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1017\/S1092852900002133","article-title":"CRHR1 antagonists as novel treatment strategies","volume":"6","author":"Holsboer","year":"2001","journal-title":"CNS Spectrums"},{"key":"10.1016\/j.pharmthera.2019.107402_bb1005","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/s41398-018-0163-1","article-title":"Association between amygdala neurokinin-1 receptor availability and anxiety-related personality traits","volume":"8","author":"Hoppe","year":"2018","journal-title":"Translational Psychiatry"},{"key":"10.1016\/j.pharmthera.2019.107402_bb1010","doi-asserted-by":"crossref","first-page":"e932","DOI":"10.4088\/JCP.14m09049","article-title":"Effect of baseline anxious depression on initial and sustained antidepressant response to ketamine","volume":"75","author":"Ionescu","year":"2014","journal-title":"The Journal of Clinical Psychiatry"},{"key":"10.1016\/j.pharmthera.2019.107402_bb1015","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1038\/s41398-017-0026-1","article-title":"DNA methylation signatures in panic disorder","volume":"7","author":"Iurato","year":"2017","journal-title":"Translational Psychiatry"},{"key":"10.1016\/j.pharmthera.2019.107402_bb1020","doi-asserted-by":"crossref","first-page":"583","DOI":"10.3233\/JAD-151146","article-title":"AVN-101: A multi-target drug candidate for the treatment of CNS disorders","volume":"53","author":"Ivachtchenko","year":"2016","journal-title":"Journal of Alzheimer's Disease"},{"key":"10.1016\/j.pharmthera.2019.107402_bb1025","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/7854_2016_56","article-title":"Role of the orexin\/Hypocretin system in stress-related psychiatric disorders","volume":"33","author":"James","year":"2017","journal-title":"Current Topics in Behavioral Neurosciences"},{"key":"10.1016\/j.pharmthera.2019.107402_bb1030","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/j.biopsych.2015.03.033","article-title":"Anxiety, stress, and fear response in mice with reduced endocannabinoid levels","volume":"79","author":"Jenniches","year":"2016","journal-title":"Biological Psychiatry"},{"key":"10.1016\/j.pharmthera.2019.107402_bb1035","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.psyneuen.2014.11.002","article-title":"The efficacy of nabilone, a synthetic cannabinoid, in the treatment of PTSD-associated nightmares: A preliminary randomized, double-blind, placebo-controlled cross-over design study","volume":"51","author":"Jetly","year":"2015","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.pharmthera.2019.107402_bb1040","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.jep.2011.06.029","article-title":"Interaction of the natural anxiolytic Galphimine-B with serotonergic drugs on dorsal hippocampus in rats","volume":"137","author":"Jimenez-Ferrer","year":"2011","journal-title":"Journal of Ethnopharmacology"},{"key":"10.1016\/j.pharmthera.2019.107402_bb1045","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.neuropharm.2018.05.012","article-title":"The abuse potential of medical psilocybin according to the 8 factors of the controlled substances act","volume":"142","author":"Johnson","year":"2018","journal-title":"Neuropharmacology."},{"key":"10.1016\/j.pharmthera.2019.107402_bb1050","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.pharmthera.2018.11.010","article-title":"Classic psychedelics: An integrative review of epidemiology, therapeutics, mystical experience, and brain network function","volume":"197","author":"Johnson","year":"2019","journal-title":"Pharmacology & Therapeutics"},{"key":"10.1016\/j.pharmthera.2019.107402_bb1055","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1152\/physrev.00031.2017","article-title":"The oxytocin receptor: From intracellular signaling to behavior","volume":"98","author":"Jurek","year":"2018","journal-title":"Physiological Reviews"},{"key":"10.1016\/j.pharmthera.2019.107402_bb1060","doi-asserted-by":"crossref","first-page":"337","DOI":"10.31887\/DCNS.2015.17.3\/akaczkurkin","article-title":"Cognitive-behavioral therapy for anxiety disorders: An update on the empirical evidence","volume":"17","author":"Kaczkurkin","year":"2015","journal-title":"Dialogues in Clinical Neuroscience"},{"key":"10.1016\/j.pharmthera.2019.107402_bb1065","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1093\/ijnp\/pyy094","article-title":"Glutamatergic neurotransmission: Pathway to developing novel rapid-acting antidepressant treatments","volume":"22","author":"Kadriu","year":"2019","journal-title":"The International Journal of Neuropsychopharmacology"},{"key":"10.1016\/j.pharmthera.2019.107402_bb1070","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/978-1-4939-9554-7_1","article-title":"Enhancing the utility of preclinical research in neuropsychiatry drug development","volume":"2011","author":"Kaffman","year":"2019","journal-title":"Methods in Molecular Biology"},{"key":"10.1016\/j.pharmthera.2019.107402_bb1075","unstructured":"Kaitin KI (2014) CNS drugs take longer to develop, have lower success rates, than other drugs. In: (Kaitin KI, ed): Tufts Center for the Study of drug development impact report."},{"key":"10.1016\/j.pharmthera.2019.107402_bb1080","series-title":"CNS drugs take 20% longer to develop and to approve vs. non-CNS drugs","author":"Kaitin","year":"2018"},{"key":"10.1016\/j.pharmthera.2019.107402_bb1085","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.euroneuro.2017.03.004","article-title":"Mechanisms underlying the early risk to develop anxiety and depression: A translational approach","volume":"27","author":"Kalin","year":"2017","journal-title":"European Neuropsychopharmacology"},{"issue":"4","key":"10.1016\/j.pharmthera.2019.107402_bb1090","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.tics.2019.01.013","article-title":"A dopaminergic basis for fear extinction","volume":"23","author":"Kalisch","year":"2019","journal-title":"Trends in Cognitive Sciences"},{"key":"10.1016\/j.pharmthera.2019.107402_bb1095","doi-asserted-by":"crossref","first-page":"730","DOI":"10.3389\/fnins.2018.00730","article-title":"Cannabis and the anxiety of fragmentation-a systems approach for finding an anxiolytic cannabis chemotype","volume":"12","author":"Kamal","year":"2018","journal-title":"Frontiers in Neuroscience"},{"key":"10.1016\/j.pharmthera.2019.107402_bb1100","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1124\/jpet.105.098319","article-title":"The pheromone androstenol (5 alpha-androst-16-en-3 alpha-ol) is a neurosteroid positive modulator of GABAA receptors","volume":"317","author":"Kaminski","year":"2006","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/j.pharmthera.2019.107402_bb1105","doi-asserted-by":"crossref","first-page":"5821","DOI":"10.1038\/s41598-019-42183-0","article-title":"Long-term benefit of microbiota transfer therapy on autism symptoms and gut microbiota","volume":"9","author":"Kang","year":"2019","journal-title":"Scientific Reports"},{"key":"10.1016\/j.pharmthera.2019.107402_bb1110","doi-asserted-by":"crossref","first-page":"330","DOI":"10.9758\/cpn.2016.14.4.330","article-title":"Neuro-stimulation techniques for the Management of Anxiety Disorders: An update","volume":"14","author":"Kar","year":"2016","journal-title":"Clinical Psychopharmacology and Neuroscience"},{"key":"10.1016\/j.pharmthera.2019.107402_bb1115","series-title":"Comorbidity of mental and physical disorders","first-page":"81","article-title":"Anxiety and related disorders and physical illness","author":"Kariuki-Nyuthe","year":"2015"},{"key":"10.1016\/j.pharmthera.2019.107402_bb1120","doi-asserted-by":"crossref","first-page":"102mr103","DOI":"10.1126\/scitranslmed.3002917","article-title":"Translational neuroscience of schizophrenia: Seeking a meeting of minds between mouse and man","volume":"3","author":"Kas","year":"2011","journal-title":"Science Translational Medicine"},{"key":"10.1016\/j.pharmthera.2019.107402_bb1125","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/S0149-7634(01)00066-5","article-title":"The neurocircuitry and receptor subtypes mediating anxiolytic-like effects of neuropeptide Y","volume":"26","author":"Kask","year":"2002","journal-title":"Neuroscience and Biobehavioral Reviews"},{"issue":"Suppl. 1","key":"10.1016\/j.pharmthera.2019.107402_bb1130","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1186\/1471-244X-14-S1-S1","article-title":"Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders","volume":"14","author":"Katzman","year":"2014","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.pharmthera.2019.107402_bb1135","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1186\/1471-244X-14-136","article-title":"A positive association between anxiety disorders and cannabis use or cannabis use disorders in the general population--a meta-analysis of 31 studies","volume":"14","author":"Kedzior","year":"2014","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.pharmthera.2019.107402_bb1140","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1016\/j.phymed.2016.10.013","article-title":"Short-term open-label chamomile (Matricaria chamomilla L.) therapy of moderate to severe generalized anxiety disorder","volume":"23","author":"Keefe","year":"2016","journal-title":"Phytomedicine"},{"key":"10.1016\/j.pharmthera.2019.107402_bb1145","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1055\/s-0035-1569371","article-title":"Does Pregnenolone enhance exposure therapy in obsessive-compulsive disorder? - a pilot, interim report of a randomized, placebo-controlled, double-blind study","volume":"49","author":"Kellner","year":"2016","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.pharmthera.2019.107402_bb1150","doi-asserted-by":"crossref","first-page":"574","DOI":"10.2174\/1570159X15666170913110426","article-title":"Neuroinflammation and the immune-kynurenine pathway in anxiety disorders","volume":"16","author":"Kim","year":"2018","journal-title":"Current Neuropharmacology"},{"key":"10.1016\/j.pharmthera.2019.107402_bb1155","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1002\/da.22481","article-title":"Altered default mode network (Dmn) resting state functional connectivity following a mindfulness-based exposure therapy for posttraumatic stress disorder (Ptsd) in combat veterans of Afghanistan and Iraq","volume":"33","author":"King","year":"2016","journal-title":"Depression and Anxiety"},{"issue":"1","key":"10.1016\/j.pharmthera.2019.107402_bb1160","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s00213-018-4999-0","article-title":"A precision medicine approach to pharmacological adjuncts to extinction: A call to broaden research","volume":"236","author":"King","year":"2018","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pharmthera.2019.107402_bb1165","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.jpsychires.2006.11.009","article-title":"Elevated plasma arginine vasopressin levels in veterans with posttraumatic stress disorder","volume":"42","author":"de Kloet","year":"2008","journal-title":"Journal of Psychiatric Research"},{"key":"10.1016\/j.pharmthera.2019.107402_bb1170","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2019.00510","article-title":"New frontiers in anxiety research: The translational potential of the bed nucleus of the stria terminalis","volume":"10","author":"Knight","year":"2019","journal-title":"Frontiers in Psychiatry"},{"key":"10.1016\/j.pharmthera.2019.107402_bb1175","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.janxdis.2017.11.003","article-title":"Long-term effectiveness of cognitive behavioral therapy for youth with anxiety disorders","volume":"53","author":"Kodal","year":"2018","journal-title":"Journal of Anxiety Disorders"},{"key":"10.1016\/j.pharmthera.2019.107402_bb1180","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1002\/da.22530","article-title":"The classification of anxiety and fear-related disorders in the ICD-11","volume":"33","author":"Kogan","year":"2016","journal-title":"Depression and Anxiety"},{"key":"10.1016\/j.pharmthera.2019.107402_bb1185","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.2147\/NDT.S167538","article-title":"Addictive potential of novel treatments for refractory depression and anxiety","volume":"14","author":"Kolar","year":"2018","journal-title":"Neuropsychiatric Disease and Treatment"},{"key":"10.1016\/j.pharmthera.2019.107402_bb1190","doi-asserted-by":"crossref","first-page":"4589","DOI":"10.1113\/jphysiol.2009.176297","article-title":"Memantine binding to a superficial site on NMDA receptors contributes to partial trapping","volume":"587","author":"Kotermanski","year":"2009","journal-title":"Journal of Physiology"},{"key":"10.1016\/j.pharmthera.2019.107402_bb1195","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.biopsych.2014.04.010","article-title":"Psilocybin-induced decrease in amygdala reactivity correlates with enhanced positive mood in healthy volunteers","volume":"78","author":"Kraehenmann","year":"2015","journal-title":"Biological Psychiatry"},{"key":"10.1016\/j.pharmthera.2019.107402_bb1200","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1097\/ALN.0b013e3182475d66","article-title":"Xenon attenuates hippocampal long-term potentiation by diminishing synaptic and extrasynaptic N-methyl-D-aspartate receptor currents","volume":"116","author":"Kratzer","year":"2012","journal-title":"Anesthesiology"},{"key":"10.1016\/j.pharmthera.2019.107402_bb1205","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.neubiorev.2017.03.007","article-title":"Serotonin and neuroplasticity - links between molecular, functional and structural pathophysiology in depression","volume":"77","author":"Kraus","year":"2017","journal-title":"Neuroscience and Biobehavioral Reviews"},{"key":"10.1016\/j.pharmthera.2019.107402_bb1210","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.smrv.2012.08.001","article-title":"Review of the histamine system and the clinical effects of H1 antagonists: Basis for a new model for understanding the effects of insomnia medications","volume":"17","author":"Krystal","year":"2013","journal-title":"Sleep Medicine Reviews"},{"key":"10.1016\/j.pharmthera.2019.107402_bb1215","doi-asserted-by":"crossref","first-page":"e51","DOI":"10.1016\/j.biopsych.2017.03.007","article-title":"It is time to address the crisis in the pharmacotherapy of posttraumatic stress disorder: A consensus statement of the PTSD psychopharmacology working group","volume":"82","author":"Krystal","year":"2017","journal-title":"Biological Psychiatry"},{"key":"10.1016\/j.pharmthera.2019.107402_bb1220","doi-asserted-by":"crossref","first-page":"268","DOI":"10.3389\/fgene.2019.00268","article-title":"Epigenetic regulations in neuropsychiatric disorders","volume":"10","author":"Kuehner","year":"2019","journal-title":"Frontiers in Genetics"},{"key":"10.1016\/j.pharmthera.2019.107402_bb1225","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1177\/0269881117699617","article-title":"Multifaceted empathy of healthy volunteers after single doses of MDMA: A pooled sample of placebo-controlled studies","volume":"31","author":"Kuypers","year":"2017","journal-title":"Journal of Psychopharmacology"},{"key":"10.1016\/j.pharmthera.2019.107402_bb1230","doi-asserted-by":"crossref","first-page":"171","DOI":"10.14310\/horm.2002.1738","article-title":"Effects of a hops (Humulus lupulus L.) dry extract supplement on self-reported depression, anxiety and stress levels in apparently healthy young adults: A randomized, placebo-controlled, double-blind, crossover pilot study","volume":"16","author":"Kyrou","year":"2017","journal-title":"Hormones (Athens, Greece)"},{"key":"10.1016\/j.pharmthera.2019.107402_bb1235","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1007\/s13311-017-0585-0","article-title":"Anxiety, depression, and the microbiome: A role for gut peptides","volume":"15","author":"Lach","year":"2018","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.pharmthera.2019.107402_bb1240","doi-asserted-by":"crossref","first-page":"167","DOI":"10.2174\/187152706776359664","article-title":"The involvement of the vasopressin system in stress-related disorders","volume":"5","author":"Landgraf","year":"2006","journal-title":"CNS & Neurological Disorders Drug Targets"},{"key":"10.1016\/j.pharmthera.2019.107402_bb1245","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.pharmthera.2019.01.002","article-title":"Novel genetic and epigenetic factors of importance for inter-individual differences in drug disposition, response and toxicity","volume":"197","author":"Lauschke","year":"2019","journal-title":"Pharmacology & Therapeutics"},{"key":"10.1016\/j.pharmthera.2019.107402_bb1250","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.tips.2011.02.013","article-title":"Personalized medicine can pave the way for the safe use of CB(1) receptor antagonists","volume":"32","author":"Lazary","year":"2011","journal-title":"Trends in Pharmacological Sciences"},{"key":"10.1016\/j.pharmthera.2019.107402_bb1255","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1146\/annurev-clinpsy-050718-095634","article-title":"Augmentation of extinction and inhibitory learning in anxiety and trauma-related disorders","volume":"15","author":"Lebois","year":"2019","journal-title":"Annual Review of Clinical Psychology"},{"key":"10.1016\/j.pharmthera.2019.107402_bb1260","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1177\/0706743716635535","article-title":"Posttraumatic stress disorder: Does the gut microbiome hold the key?","volume":"61","author":"Leclercq","year":"2016","journal-title":"Canadian Journal of Psychiatry"},{"key":"10.1016\/j.pharmthera.2019.107402_bb1265","doi-asserted-by":"crossref","first-page":"100","DOI":"10.3389\/fnsys.2013.00100","article-title":"A novel V1a receptor antagonist blocks vasopressin-induced changes in the CNS response to emotional stimuli: An fMRI study","volume":"7","author":"Lee","year":"2013","journal-title":"Frontiers in Systems Neuroscience"},{"key":"10.1016\/j.pharmthera.2019.107402_bb1270","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.biopsych.2012.09.004","article-title":"Benzodiazepines counteract rostral anterior cingulate cortex activation induced by cholecystokinin-tetrapeptide in humans","volume":"73","author":"Leicht","year":"2013","journal-title":"Biological Psychiatry"},{"key":"10.1016\/j.pharmthera.2019.107402_bb1275","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/nrneurol.2016.13","article-title":"Ultrasound treatment of neurological diseases--current and emerging applications","volume":"12","author":"Leinenga","year":"2016","journal-title":"Nature Reviews. Neurology"},{"key":"10.1016\/j.pharmthera.2019.107402_bb1280","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.biopsych.2015.05.003","article-title":"Intranasal oxytocin: Myths and delusions","volume":"79","author":"Leng","year":"2016","journal-title":"Biological Psychiatry"},{"key":"10.1016\/j.pharmthera.2019.107402_bb1285","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.2147\/NDT.S67470","article-title":"Profile of agomelatine and its potential in the treatment of generalized anxiety disorder","volume":"11","author":"Levitan","year":"2015","journal-title":"Neuropsychiatric Disease and Treatment"},{"key":"10.1016\/j.pharmthera.2019.107402_bb1290","series-title":"Charney & Nestler's neurobiology of mental illness","first-page":"477","article-title":"Synaptic Neurocircuitry and neuroimaging studies of anxiety disorders","author":"Li","year":"2018"},{"key":"10.1016\/j.pharmthera.2019.107402_bb1295","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1002\/da.22546","article-title":"Effect of as-needed use of intranasal PH94B on social and performance anxiety in individuals with social anxiety disorder","volume":"33","author":"Liebowitz","year":"2016","journal-title":"Depression and Anxiety"},{"key":"10.1016\/j.pharmthera.2019.107402_bb1300","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1176\/appi.ajp.2014.12101342","article-title":"Effect of an acute intranasal aerosol dose of PH94B on social and performance anxiety in women with social anxiety disorder","volume":"171","author":"Liebowitz","year":"2014","journal-title":"The American Journal of Psychiatry"},{"key":"10.1016\/j.pharmthera.2019.107402_bb1305","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1038\/npp.2017.86","article-title":"Modern clinical research on LSD","volume":"42","author":"Liechti","year":"2017","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pharmthera.2019.107402_bb1310","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s00213-018-5127-x","article-title":"Tempering aversive\/traumatic memories with cannabinoids: A review of evidence from animal and human studies","volume":"236","author":"Lisboa","year":"2019","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pharmthera.2019.107402_bb1315","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.cpr.2015.08.004","article-title":"Response rates for CBT for anxiety disorders: Need for standardized criteria","volume":"42","author":"Loerinc","year":"2015","journal-title":"Clinical Psychology Review"},{"key":"10.1016\/j.pharmthera.2019.107402_bb1320","doi-asserted-by":"crossref","first-page":"55","DOI":"10.3389\/fendo.2011.00055","article-title":"Neurosteroids as neuromodulators in the treatment of anxiety disorders","volume":"2","author":"Longone","year":"2011","journal-title":"Frontiers in Endocrinology"},{"key":"10.1016\/j.pharmthera.2019.107402_bb1325","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.janxdis.2011.01.002","article-title":"The discovery of chlordiazepoxide and the clinical introduction of benzodiazepines: half a century of anxiolytic drugs","volume":"25","author":"Lopez-Munoz","year":"2011","journal-title":"Journal of Anxiety Disorder"},{"issue":"1","key":"10.1016\/j.pharmthera.2019.107402_bb1330","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s00213-018-5104-4","article-title":"Mechanisms of fear learning and extinction: Synaptic plasticity-fear memory connection","volume":"236","author":"Luchkina","year":"2018","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pharmthera.2019.107402_bb1335","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.neubiorev.2016.04.005","article-title":"Neurobiological markers predicting treatment response in anxiety disorders: A systematic review and implications for clinical application","volume":"66","author":"Lueken","year":"2016","journal-title":"Neuroscience and Biobehavioral Reviews"},{"key":"10.1016\/j.pharmthera.2019.107402_bb1340","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1038\/s41467-018-04784-7","article-title":"A dopaminergic switch for fear to safety transitions","volume":"9","author":"Luo","year":"2018","journal-title":"Nature Communications"},{"key":"10.1016\/j.pharmthera.2019.107402_bb1345","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1124\/jpet.114.213793","article-title":"Brexpiprazole I: In vitro and in vivo characterization of a novel serotonin-dopamine activity modulator","volume":"350","author":"Maeda","year":"2014","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/j.pharmthera.2019.107402_bb1350","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.tins.2011.06.007","article-title":"Fear conditioning, synaptic plasticity and the amygdala: Implications for posttraumatic stress disorder","volume":"35","author":"Mahan","year":"2012","journal-title":"Trends in Neurosciences"},{"key":"10.1016\/j.pharmthera.2019.107402_bb1355","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0195521","article-title":"Population scale retrospective analysis reveals distinctive antidepressant and anxiolytic effects of diclofenac, ketoprofen and naproxen in patients with pain","volume":"13","author":"Makunts","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmthera.2019.107402_bb1360","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.17r11839","article-title":"Association of Cannabis with Long-Term Clinical Symptoms in anxiety and mood disorders: A systematic review of prospective studies","volume":"79","author":"Mammen","year":"2018","journal-title":"The Journal of Clinical Psychiatry"},{"key":"10.1016\/j.pharmthera.2019.107402_bb1365","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1517\/13543784.2014.998335","article-title":"Discontinued anxiolytic drugs (2009 - 2014)","volume":"24","author":"Mandrioli","year":"2015","journal-title":"Expert Opinion on Investigational Drugs"},{"key":"10.1016\/j.pharmthera.2019.107402_bb1370","doi-asserted-by":"crossref","DOI":"10.1038\/tp.2015.218","article-title":"Neuroplasticity in response to cognitive behavior therapy for social anxiety disorder","volume":"6","author":"Mansson","year":"2016","journal-title":"Translational Psychiatry"},{"key":"10.1016\/j.pharmthera.2019.107402_bb1375","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.bbr.2016.11.018","article-title":"Structural but not functional neuroplasticity one year after effective cognitive behaviour therapy for social anxiety disorder","volume":"318","author":"Mansson","year":"2017","journal-title":"Behavioural Brain Research"},{"key":"10.1016\/j.pharmthera.2019.107402_bb1380","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1016\/j.phymed.2016.10.012","article-title":"Long-term chamomile (Matricaria chamomilla L.) treatment for generalized anxiety disorder: A randomized clinical trial","volume":"23","author":"Mao","year":"2016","journal-title":"Phytomedicine"},{"key":"10.1016\/j.pharmthera.2019.107402_bb1385","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1002\/cne.1190","article-title":"Differential expression of orexin receptors 1 and 2 in the rat brain","volume":"435","author":"Marcus","year":"2001","journal-title":"The Journal of Comparative Neurology"},{"key":"10.1016\/j.pharmthera.2019.107402_bb1390","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/7854_2018_49","article-title":"Imaging and genetic approaches to inform biomarkers for anxiety disorders, obsessive-compulsive disorders, and PSTD","volume":"40","author":"Maron","year":"2018","journal-title":"Current Topics in Behavioral Neurosciences"},{"key":"10.1016\/j.pharmthera.2019.107402_bb1395","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1001\/jamapsychiatry.2016.3955","article-title":"D-Cycloserine augmentation of exposure-based cognitive behavior therapy for anxiety, obsessive-compulsive, and posttraumatic stress disorders: A systematic review and meta-analysis of individual participant data","volume":"74","author":"Mataix-Cols","year":"2017","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.pharmthera.2019.107402_bb1400","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1176\/appi.ajp.162.12.2379","article-title":"Open-label trial of riluzole in generalized anxiety disorder","volume":"162","author":"Mathew","year":"2005","journal-title":"The American Journal of Psychiatry"},{"key":"10.1016\/j.pharmthera.2019.107402_bb1405","doi-asserted-by":"crossref","first-page":"2567","DOI":"10.1038\/npp.2017.106","article-title":"A randomized, double-blind, placebo-controlled, sequential parallel comparison design trial of adjunctive Riluzole for treatment-resistant major depressive disorder","volume":"42","author":"Mathew","year":"2017","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pharmthera.2019.107402_bb1410","doi-asserted-by":"crossref","first-page":"104250","DOI":"10.1016\/j.phrs.2019.04.034","article-title":"Involvement of the GABAA receptor alpha subunit in the mode of action of etifoxine","volume":"145","author":"Mattei","year":"2019","journal-title":"Pharmacological Research"},{"key":"10.1016\/j.pharmthera.2019.107402_bb1415","article-title":"Elevated anandamide, enhanced recall of fear extinction, and attenuated stress responses following inhibition of fatty acid amide hydrolase (FAAH): A randomized, controlled experimental medicine trial","author":"Mayo","year":"2019","journal-title":"Biological Psychiatry"},{"key":"10.1016\/j.pharmthera.2019.107402_bb1420","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.neubiorev.2017.02.004","article-title":"Aligning physiology with psychology: Translational neuroscience in neuropsychiatric drug discovery","volume":"76","author":"McArthur","year":"2017","journal-title":"Neuroscience and Biobehavioral Reviews"},{"key":"10.1016\/j.pharmthera.2019.107402_bb1425","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1038\/npp.2017.19","article-title":"Prophylactic ketamine attenuates learned fear","volume":"42","author":"McGowan","year":"2017","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pharmthera.2019.107402_bb1430","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s12906-016-1022-3","article-title":"Herbal medicine use behaviour in Australian adults who experience anxiety: A descriptive study","volume":"16","author":"McIntyre","year":"2016","journal-title":"BMC Complementary and Alternative Medicine"},{"key":"10.1016\/j.pharmthera.2019.107402_bb1435","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1002\/da.22284","article-title":"Amygdala response to negative stimuli predicts PTSD symptom onset following a terrorist attack","volume":"31","author":"McLaughlin","year":"2014","journal-title":"Depression and Anxiety"},{"key":"10.1016\/j.pharmthera.2019.107402_bb1440","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1080\/03036758.2017.1358184","article-title":"What do you mean \u2018anxiety\u2019? Developing the first anxiety syndrome biomarker","volume":"48","author":"McNaughton","year":"2018","journal-title":"Journal of the Royal Society of New Zealand"},{"key":"10.1016\/j.pharmthera.2019.107402_bb1445","doi-asserted-by":"crossref","DOI":"10.1001\/jamapsychiatry.2019.1119","article-title":"Genetic variants associated with anxiety and stress-related disorders: A genome-wide association study and mouse-model study","author":"Meier","year":"2019","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.pharmthera.2019.107402_bb1450","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0106189","article-title":"Xenon impairs reconsolidation of fear memories in a rat model of post-traumatic stress disorder (PTSD)","volume":"9","author":"Meloni","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmthera.2019.107402_bb1455","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0301-0082(03)00087-X","article-title":"The neurobiology and control of anxious states","volume":"70","author":"Millan","year":"2003","journal-title":"Progress in Neurobiology"},{"key":"10.1016\/j.pharmthera.2019.107402_bb1460","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1124\/jpet.103.051797","article-title":"The novel melatonin agonist agomelatine (S20098) is an antagonist at 5-hydroxytryptamine2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways","volume":"306","author":"Millan","year":"2003","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/j.pharmthera.2019.107402_bb1465","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.euroneuro.2015.01.016","article-title":"Learning from the past and looking to the future: Emerging perspectives for improving the treatment of psychiatric disorders","volume":"25","author":"Millan","year":"2015","journal-title":"European Neuropsychopharmacology"},{"key":"10.1016\/j.pharmthera.2019.107402_bb1470","doi-asserted-by":"crossref","unstructured":"Mithoefer MC, Feduccia AA, Jerome L, Mithoefer A, Wagner M, Walsh Z, Hamilton S, Yazar-Klosinski B, Emerson A, Doblin R (2019) MDMA-assisted psychotherapy for treatment of PTSD: Study design and rationale for phase 3 trials based on pooled analysis of six phase 2 randomized controlled trials. Psychopharmacology (Berl).","DOI":"10.1007\/s00213-019-05249-5"},{"key":"10.1016\/j.pharmthera.2019.107402_bb1475","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/S2215-0366(18)30135-4","article-title":"3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for post-traumatic stress disorder in military veterans, firefighters, and police officers: A randomised, double-blind, dose-response, phase 2 clinical trial","volume":"5","author":"Mithoefer","year":"2018","journal-title":"The Lancet Psychiatry"},{"key":"10.1016\/j.pharmthera.2019.107402_bb1480","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1177\/0269881112456611","article-title":"Durability of improvement in post-traumatic stress disorder symptoms and absence of harmful effects or drug dependency after 3,4-methylenedioxymethamphetamine-assisted psychotherapy: A prospective long-term follow-up study","volume":"27","author":"Mithoefer","year":"2013","journal-title":"Journal of Psychopharmacology"},{"key":"10.1016\/j.pharmthera.2019.107402_bb1485","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1097\/01.jcp.0000155821.74832.f9","article-title":"A meta-analytic review of the efficacy of drug treatment in generalized anxiety disorder","volume":"25","author":"Mitte","year":"2005","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1016\/j.pharmthera.2019.107402_bb1490","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.cub.2016.02.031","article-title":"Ancient anxiety pathways influence drosophila defense behaviors","volume":"26","author":"Mohammad","year":"2016","journal-title":"Current Biology"},{"key":"10.1016\/j.pharmthera.2019.107402_bb1495","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1111\/nmo.12675","article-title":"Early-life stress-induced visceral hypersensitivity and anxiety behavior is reversed by histone deacetylase inhibition","volume":"27","author":"Moloney","year":"2015","journal-title":"Neurogastroenterology and Motility"},{"key":"10.1016\/j.pharmthera.2019.107402_bb1500","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.smrv.2010.11.003","article-title":"Serotonin control of sleep-wake behavior","volume":"15","author":"Monti","year":"2011","journal-title":"Sleep Medicine Reviews"},{"key":"10.1016\/j.pharmthera.2019.107402_bb1505","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.4088\/JCP.v67n1110","article-title":"Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder","volume":"67","author":"Moreno","year":"2006","journal-title":"The Journal of Clinical Psychiatry"},{"key":"10.1016\/j.pharmthera.2019.107402_bb1510","doi-asserted-by":"crossref","DOI":"10.1038\/tp.2017.54","article-title":"Acute effects of LSD on amygdala activity during processing of fearful stimuli in healthy subjects","volume":"7","author":"Mueller","year":"2017","journal-title":"Translational Psychiatry"},{"key":"10.1016\/j.pharmthera.2019.107402_bb1515","doi-asserted-by":"crossref","DOI":"10.1111\/gbb.12427","article-title":"Potential of microRNAs as novel targets in the alleviation of pathological fear","volume":"17","author":"Murphy","year":"2018","journal-title":"Genes, Brain, and Behavior"},{"key":"10.1016\/j.pharmthera.2019.107402_bb1520","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1517\/14728214.2015.1049996","article-title":"Emerging drugs for the treatment of anxiety","volume":"20","author":"Murrough","year":"2015","journal-title":"Expert Opinion on Emerging Drugs"},{"issue":"1","key":"10.1016\/j.pharmthera.2019.107402_bb1525","first-page":"100","article-title":"Prazosin use during prolonged exposure therapy with veterans: An examination of treatment effectiveness","volume":"7","author":"Myers","year":"2019","journal-title":"Military Behavioral Health"},{"key":"10.1016\/j.pharmthera.2019.107402_bb1530","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1097\/JCP.0b013e31828b26c2","article-title":"Trait anxiety levels before and after antidepressant treatment: A 3-wave cohort study","volume":"33","author":"Nabi","year":"2013","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1016\/j.pharmthera.2019.107402_bb1535","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s11920-017-0819-1","article-title":"Oxytocin and anxiety disorders: Translational and therapeutic aspects","volume":"19","author":"Naja","year":"2017","journal-title":"Current Psychiatry Reports"},{"issue":"5","key":"10.1016\/j.pharmthera.2019.107402_bb1540","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1007\/s00406-018-0945-8","article-title":"Cognitive-behavioral therapy effects on alerting network activity and effective connectivity in panic disorder","volume":"269","author":"Neufang","year":"2019","journal-title":"European Archives of Psychiatry and Clinical Neuroscience"},{"key":"10.1016\/j.pharmthera.2019.107402_bb1545","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.biopsych.2015.06.004","article-title":"Oxytocin in general anxiety and social fear: A translational approach","volume":"79","author":"Neumann","year":"2016","journal-title":"Biological Psychiatry"},{"key":"10.1016\/j.pharmthera.2019.107402_bb1550","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1038\/mp.2013.61","article-title":"Elevated brain cannabinoid CB1 receptor availability in post-traumatic stress disorder: A positron emission tomography study","volume":"18","author":"Neumeister","year":"2013","journal-title":"Molecular Psychiatry"},{"key":"10.1016\/j.pharmthera.2019.107402_bb1555","doi-asserted-by":"crossref","DOI":"10.1177\/2398212818804030","article-title":"The research domain criteria framework in drug discovery for neuropsychiatric diseases: Focus on negative valence","volume":"2","author":"Nicholson","year":"2018","journal-title":"Brain and Neuroscience Advances"},{"key":"10.1016\/j.pharmthera.2019.107402_bb1560","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.pbb.2016.05.006","article-title":"Don't worry; be informed about the epigenetics of anxiety","volume":"146-147","author":"Nieto","year":"2016","journal-title":"Pharmacology, Biochemistry, and Behavior"},{"key":"10.1016\/j.pharmthera.2019.107402_bb1565","author":"NobilisTherapeutics"},{"key":"10.1016\/j.pharmthera.2019.107402_bb1570","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1002\/jclp.22144","article-title":"A systematic review of mindfulness and acceptance-based treatments for social anxiety disorder","volume":"71","author":"Norton","year":"2015","journal-title":"Journal of Clinical Psychology"},{"key":"10.1016\/j.pharmthera.2019.107402_bb1575","first-page":"165","article-title":"Anxiety disorders and GABA neurotransmission: A disturbance of modulation","volume":"11","author":"Nuss","year":"2015","journal-title":"Neuropsychiatric Disease and Treatment"},{"key":"10.1016\/j.pharmthera.2019.107402_bb1580","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.2147\/NDT.S200568","article-title":"An update on the anxiolytic and neuroprotective properties of etifoxine: From brain GABA modulation to a whole-body mode of action","volume":"15","author":"Nuss","year":"2019","journal-title":"Neuropsychiatric Disease and Treatment"},{"key":"10.1016\/j.pharmthera.2019.107402_bb1585","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.nbd.2013.05.002","article-title":"CNS drug development in Europe--past progress and future challenges","volume":"61","author":"Nutt","year":"2014","journal-title":"Neurobiology of Disease"},{"key":"10.1016\/j.pharmthera.2019.107402_bb1590","first-page":"107703","article-title":"Different roles of distinct serotonergic pathways in anxiety-like behavior, antidepressant-like, and anti-impulsive effects","author":"Ohmura","year":"2019","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pharmthera.2019.107402_bb1595","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1111\/j.1468-1331.2011.03590.x","article-title":"The economic cost of brain disorders in Europe","volume":"19","author":"Olesen","year":"2012","journal-title":"European Journal of Neurology"},{"key":"10.1016\/j.pharmthera.2019.107402_bb1600","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.ejphar.2014.10.031","article-title":"Serotonin: A never-ending story","volume":"753","author":"Olivier","year":"2015","journal-title":"European Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2019.107402_bb1605","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.neuropharm.2008.07.045","article-title":"GABA a receptors: Subtypes provide diversity of function and pharmacology","volume":"56","author":"Olsen","year":"2009","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pharmthera.2019.107402_bb1610","doi-asserted-by":"crossref","DOI":"10.1177\/1179069518800508","article-title":"Psychoplastogens: A promising class of plasticity-promoting neurotherapeutics","volume":"12","author":"Olson","year":"2018","journal-title":"Journal of Experimental Neuroscience"},{"key":"10.1016\/j.pharmthera.2019.107402_bb1615","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1089\/acm.2018.0001","article-title":"Kava for generalized anxiety disorder: A review of current evidence","volume":"24","author":"Ooi","year":"2018","journal-title":"Journal of Alternative and Complementary Medicine"},{"key":"10.1016\/j.pharmthera.2019.107402_bb1620","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1038\/mp.2015.197","article-title":"Meta-analysis of genome-wide association studies of anxiety disorders","volume":"21","author":"Otowa","year":"2016","journal-title":"Molecular Psychiatry"},{"key":"10.1016\/j.pharmthera.2019.107402_bb1625","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.biopsych.2015.09.007","article-title":"Enhancement of psychosocial treatment with D-cycloserine: Models, moderators, and future directions","volume":"80","author":"Otto","year":"2016","journal-title":"Biological Psychiatry"},{"key":"10.1016\/j.pharmthera.2019.107402_bb1630","series-title":"The function of emotions: When and why emotions help us","first-page":"9","article-title":"Fear and anxiety","author":"Parsafar","year":"2018"},{"key":"10.1016\/j.pharmthera.2019.107402_bb1635","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/S2215-0366(15)00309-0","article-title":"Inflammatory markers in post-traumatic stress disorder: A systematic review, meta-analysis, and meta-regression","volume":"2","author":"Passos","year":"2015","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.pharmthera.2019.107402_bb1640","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.neubiorev.2016.12.033","article-title":"The endocannabinoid system as a target for novel anxiolytic drugs","volume":"76","author":"Patel","year":"2017","journal-title":"Neuroscience and Biobehavioral Reviews"},{"key":"10.1016\/j.pharmthera.2019.107402_bb1645","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1101\/lm.039180.115","article-title":"Neurobehavioral perspectives on the distinction between fear and anxiety","volume":"22","author":"Perusini","year":"2015","journal-title":"Learning & Memory"},{"key":"10.1016\/j.pharmthera.2019.107402_bb1650","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.psyneuen.2018.05.005","article-title":"Stress-induced pro- and anti-inflammatory cytokine concentrations in panic disorder patients","volume":"94","author":"Petrowski","year":"2018","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.pharmthera.2019.107402_bb1655","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1186\/s12864-018-4929-x","article-title":"Gene expression analysis indicates reduced memory and cognitive functions in the hippocampus and increase in synaptic reorganization in the frontal cortex 3 weeks after MDMA administration in dark Agouti rats","volume":"19","author":"Petschner","year":"2018","journal-title":"BMC Genomics"},{"key":"10.1016\/j.pharmthera.2019.107402_bb1660","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.biopsych.2012.10.003","article-title":"Corticolimbic brain reactivity to social signals of threat before and after sertraline treatment in generalized social phobia","volume":"73","author":"Phan","year":"2013","journal-title":"Biological Psychiatry"},{"issue":"7767","key":"10.1016\/j.pharmthera.2019.107402_bb1665","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/s41586-019-1433-7","article-title":"Memory editing from science fiction to clinical practice","volume":"572","author":"Phelps","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2019.107402_bb1670","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1038\/nrn3339","article-title":"Biological studies of post-traumatic stress disorder","volume":"13","author":"Pitman","year":"2012","journal-title":"Nature Reviews. Neuroscience"},{"key":"10.1016\/j.pharmthera.2019.107402_bb1675","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S0006-3223(01)01279-3","article-title":"Pilot study of secondary prevention of posttraumatic stress disorder with propranolol","volume":"51","author":"Pitman","year":"2002","journal-title":"Biological Psychiatry"},{"key":"10.1016\/j.pharmthera.2019.107402_bb1680","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.4088\/JCP.14m09123","article-title":"Riluzole augmentation in treatment-refractory obsessive-compulsive disorder: A pilot randomized placebo-controlled trial","volume":"76","author":"Pittenger","year":"2015","journal-title":"The Journal of Clinical Psychiatry"},{"key":"10.1016\/j.pharmthera.2019.107402_bb1685","first-page":"CD003383","article-title":"Kava extract for treating anxiety","author":"Pittler","year":"2003","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1016\/j.pharmthera.2019.107402_bb1690","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.neuropharm.2017.07.021","article-title":"Elucidation of the neural circuits activated by a GABAB receptor positive modulator: Relevance to anxiety","volume":"136","author":"Pizzo","year":"2018","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pharmthera.2019.107402_bb1695","doi-asserted-by":"crossref","first-page":"S36","DOI":"10.1080\/15622975.2018.1468030","article-title":"Anxiolytics targeting GABAA receptors: Insights on etifoxine","volume":"19","author":"Poisbeau","year":"2018","journal-title":"The World Journal of Biological Psychiatry"},{"issue":"2","key":"10.1016\/j.pharmthera.2019.107402_bb1700","first-page":"84","article-title":"Novel benzodiazepine-like ligands with various anxiolytic, antidepressant, or pro-cognitive profiles","volume":"5","author":"Prevot","year":"2019","journal-title":"Molecular Neuropsychiatry"},{"key":"10.1016\/j.pharmthera.2019.107402_bb1705","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.2174\/13816128113199990437","article-title":"Cannabinoid modulation of fear extinction brain circuits: A novel target to advance anxiety treatment","volume":"20","author":"Rabinak","year":"2014","journal-title":"Current Pharmaceutical Design"},{"key":"10.1016\/j.pharmthera.2019.107402_bb1710","doi-asserted-by":"crossref","DOI":"10.4088\/PCC.17m02138","article-title":"A double-blind, placebo-controlled randomized trial of Vilazodone in the treatment of posttraumatic stress disorder and comorbid depression","volume":"19","author":"Ramaswamy","year":"2017","journal-title":"The Primary Care Companion for CNS Disorders"},{"key":"10.1016\/j.pharmthera.2019.107402_bb1715","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s40169-017-0181-2","article-title":"A perspective on multi-target drug discovery and design for complex diseases","volume":"7","author":"Ramsay","year":"2018","journal-title":"Clinical and Translational Medicine"},{"key":"10.1016\/j.pharmthera.2019.107402_bb1720","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/j.psychres.2015.07.009","article-title":"Plasma cytokine abnormalities in drug-naive, comorbidity-free obsessive-compulsive disorder","volume":"229","author":"Rao","year":"2015","journal-title":"Psychiatry Research"},{"key":"10.1016\/j.pharmthera.2019.107402_bb1725","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1007\/s11920-018-0908-9","article-title":"Neurotransmitter, peptide, and steroid hormone abnormalities in PTSD: Biological Endophenotypes relevant to treatment","volume":"20","author":"Rasmusson","year":"2018","journal-title":"Current Psychiatry Reports"},{"key":"10.1016\/j.pharmthera.2019.107402_bb1730","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/wps.20611","article-title":"Innovations and changes in the ICD-11 classification of mental, behavioural and neurodevelopmental disorders","volume":"18","author":"Reed","year":"2019","journal-title":"World Psychiatry"},{"key":"10.1016\/j.pharmthera.2019.107402_bb1735","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/bs.pmbts.2018.03.002","article-title":"Neuroepigenetics of Neurotrophin signaling: Neurobiology of anxiety and affective disorders","volume":"158","author":"Regue-Guyon","year":"2018","journal-title":"Progress in Molecular Biology and Translational Science"},{"key":"10.1016\/j.pharmthera.2019.107402_bb1740","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.npep.2015.09.008","article-title":"Neuropeptide Y: A stressful review","volume":"55","author":"Reichmann","year":"2016","journal-title":"Neuropeptides"},{"key":"10.1016\/j.pharmthera.2019.107402_bb1745","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/j.neuron.2018.05.018","article-title":"Glutamatergic signaling in the central nervous system: Ionotropic and metabotropic receptors in concert","volume":"98","author":"Reiner","year":"2018","journal-title":"Neuron"},{"key":"10.1016\/j.pharmthera.2019.107402_bb1750","doi-asserted-by":"crossref","DOI":"10.1002\/brb3.497","article-title":"A systematic review of reviews on the prevalence of anxiety disorders in adult populations","volume":"6","author":"Remes","year":"2016","journal-title":"Brain and Behavior: A Cognitive Neuroscience Perspective"},{"key":"10.1016\/j.pharmthera.2019.107402_bb1755","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1001\/archpsyc.61.11.1136","article-title":"Cognitive enhancers as adjuncts to psychotherapy: Use of D-cycloserine in phobic individuals to facilitate extinction of fear","volume":"61","author":"Ressler","year":"2004","journal-title":"Archives of General Psychiatry"},{"key":"10.1016\/j.pharmthera.2019.107402_bb1760","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jad.2011.11.014","article-title":"Humanistic and economic burden of generalized anxiety disorder in North America and Europe","volume":"140","author":"Revicki","year":"2012","journal-title":"Journal of Affective Disorders"},{"key":"10.1016\/j.pharmthera.2019.107402_bb1765","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1101\/lm.78204","article-title":"Facilitation of fear extinction by D-cycloserine: Theoretical and clinical implications","volume":"11","author":"Richardson","year":"2004","journal-title":"Learning & Memory"},{"key":"10.1016\/j.pharmthera.2019.107402_bb1770","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1016\/S0149-2918(03)80159-5","article-title":"A review of the efficacy and tolerability of immediate-release and extended-release formulations of gepirone","volume":"25","author":"Robinson","year":"2003","journal-title":"Clinical Therapeutics"},{"key":"10.1016\/j.pharmthera.2019.107402_bb1775","doi-asserted-by":"crossref","DOI":"10.1136\/jnnp-2019-321400","article-title":"The translational neural circuitry of anxiety","author":"Robinson","year":"2019","journal-title":"Journal of Neurology, Neurosurgery, and Psychiatry"},{"key":"10.1016\/j.pharmthera.2019.107402_bb1780","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1038\/npp.2013.150","article-title":"Randomized controlled crossover trial of ketamine in obsessive-compulsive disorder: Proof-of-concept","volume":"38","author":"Rodriguez","year":"2013","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pharmthera.2019.107402_bb1785","doi-asserted-by":"crossref","first-page":"1037036","DOI":"10.1155\/2019\/1037036","article-title":"Galphimine-B standardized extract versus alprazolam in patients with generalized anxiety disorder: A ten-week, double-blind, randomized clinical trial","volume":"2019","author":"Romero-Cerecero","year":"2019","journal-title":"BioMed Research International"},{"key":"10.1016\/j.pharmthera.2019.107402_bb1790","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1177\/0269881116675512","article-title":"Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: A randomized controlled trial","volume":"30","author":"Ross","year":"2016","journal-title":"Journal of Psychopharmacology"},{"key":"10.1016\/j.pharmthera.2019.107402_bb1795","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1176\/appi.ajp.2014.13121625","article-title":"A randomized, double-blind evaluation of D-cycloserine or alprazolam combined with virtual reality exposure therapy for posttraumatic stress disorder in Iraq and Afghanistan War veterans","volume":"171","author":"Rothbaum","year":"2014","journal-title":"The American Journal of Psychiatry"},{"key":"10.1016\/j.pharmthera.2019.107402_bb1800","doi-asserted-by":"crossref","first-page":"191","DOI":"10.31887\/DCNS.2015.17.2\/proybyrne","article-title":"Treatment-refractory anxiety; definition, risk factors, and treatment challenges","volume":"17","author":"Roy-Byrne","year":"2015","journal-title":"Dialogues in Clinical Neuroscience"},{"key":"10.1016\/j.pharmthera.2019.107402_bb1805","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.biopha.2018.12.133","article-title":"Applications of nanotechnology in drug delivery to the central nervous system","volume":"111","author":"Saeedi","year":"2019","journal-title":"Biomedicine & Pharmacotherapy"},{"issue":"4","key":"10.1016\/j.pharmthera.2019.107402_bb1810","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1093\/ijnp\/pyz004","article-title":"Epigenetic mechanisms within the cingulate cortex regulate innate anxiety-like behavior","volume":"22","author":"Sah","year":"2019","journal-title":"The International Journal of Neuropsychopharmacology"},{"key":"10.1016\/j.pharmthera.2019.107402_bb1815","first-page":"7","article-title":"Dopamine neurons drive fear extinction learning by signaling the omission of expected aversive outcomes","author":"Salinas-Hernandez","year":"2018","journal-title":"Elife"},{"key":"10.1016\/j.pharmthera.2019.107402_bb1820","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1002\/da.22875","article-title":"Efficacy of intravenous ketamine treatment in anxious versus nonanxious unipolar treatment-resistant depression","volume":"36","author":"Salloum","year":"2019","journal-title":"Depression and Anxiety"},{"key":"10.1016\/j.pharmthera.2019.107402_bb1825","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.1176\/appi.ajp.161.11.2132","article-title":"Riluzole augmentation for treatment-resistant depression","volume":"161","author":"Sanacora","year":"2004","journal-title":"The American Journal of Psychiatry"},{"key":"10.1016\/j.pharmthera.2019.107402_bb1830","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1590\/1516-4446-2018-0005","article-title":"Anxiolytic properties of compounds that counteract oxidative stress, neuroinflammation, and glutamatergic dysfunction: A review","volume":"41","author":"Santos","year":"2019","journal-title":"Brazilian Journal of Psychiatry"},{"key":"10.1016\/j.pharmthera.2019.107402_bb1835","doi-asserted-by":"crossref","first-page":"531","DOI":"10.2217\/fnl.11.34","article-title":"The clinical implications of mouse models of enhanced anxiety","volume":"6","author":"Sartori","year":"2011","journal-title":"Future Neurology"},{"key":"10.1016\/j.pharmthera.2019.107402_bb1840","doi-asserted-by":"crossref","first-page":"A145","DOI":"10.1515\/nf-2017-A011","article-title":"New pharmacological strategies for augmenting extinction learning in anxiety disorders","volume":"23","author":"Sartori","year":"2017","journal-title":"Neuroforum"},{"key":"10.1016\/j.pharmthera.2019.107402_bb1845","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1002\/ajmg.b.32459","article-title":"The genetics of anxiety-related negative valence system traits","volume":"174","author":"Savage","year":"2017","journal-title":"American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics"},{"key":"10.1016\/j.pharmthera.2019.107402_bb1850","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/ptr.5940","article-title":"GABA-modulating phytomedicines for anxiety: A systematic review of preclinical and clinical evidence","volume":"32","author":"Savage","year":"2018","journal-title":"Phytotherapy Research"},{"key":"10.1016\/j.pharmthera.2019.107402_bb1855","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1093\/ijnp\/pyx109","article-title":"A randomized dose-ranging study of neuropeptide Y in patients with posttraumatic stress disorder","volume":"21","author":"Sayed","year":"2018","journal-title":"The International Journal of Neuropsychopharmacology"},{"key":"10.1016\/j.pharmthera.2019.107402_bb1860","doi-asserted-by":"crossref","DOI":"10.1111\/gbb.12423","article-title":"Epigenetics at the crossroads between genes, environment and resilience in anxiety disorders","volume":"17","author":"Schiele","year":"2018","journal-title":"Genes, Brain, and Behavior"},{"key":"10.1016\/j.pharmthera.2019.107402_bb1865","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1111\/cns.13115","article-title":"Pregabalin: A range of misuse-related unanswered questions","volume":"25","author":"Schifano","year":"2019","journal-title":"CNS Neuroscience & Therapeutics"},{"key":"10.1016\/j.pharmthera.2019.107402_bb1870","article-title":"Neuroanatomy of anxiety: A brief review","volume":"10","author":"Schmidt","year":"2018","journal-title":"Cureus"},{"key":"10.1016\/j.pharmthera.2019.107402_bb1875","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1002\/da.22693","article-title":"A randomized controlled pilot trial of vilazodone for adult separation anxiety disorder","volume":"34","author":"Schneier","year":"2017","journal-title":"Depression and Anxiety"},{"key":"10.1016\/j.pharmthera.2019.107402_bb1880","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1177\/0269881109104864","article-title":"Effects of lorazepam on brain activity pattern during an anxiety symptom provocation challenge","volume":"24","author":"Schunck","year":"2010","journal-title":"Journal of Psychopharmacology"},{"key":"10.1016\/j.pharmthera.2019.107402_bb1885","doi-asserted-by":"crossref","DOI":"10.4172\/2155-6105.1000e107","article-title":"DSM V, RDoC and diagnostic approaches in addiction research and therapy","volume":"3","author":"Sch\u00fctz","year":"2012","journal-title":"Journal of Addiction Research & Therapy"},{"key":"10.1016\/j.pharmthera.2019.107402_bb1890","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1517\/13543784.2014.997873","article-title":"Thinking small: Towards microRNA-based therapeutics for anxiety disorders","volume":"24","author":"Scott","year":"2015","journal-title":"Expert Opinion on Investigational Drugs"},{"key":"10.1016\/j.pharmthera.2019.107402_bb1895","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s12991-018-0190-6","article-title":"An open-label, flexible dose adaptive study evaluating the efficacy of vortioxetine in subjects with panic disorder","volume":"17","author":"Shah","year":"2018","journal-title":"Annals of General Psychiatry"},{"key":"10.1016\/j.pharmthera.2019.107402_bb1900","doi-asserted-by":"crossref","first-page":"3899","DOI":"10.2147\/DDDT.S122085","article-title":"Efficacy and tolerability of vilazodone for major depressive disorder: Evidence from phase III\/IV randomized controlled trials","volume":"10","author":"Shi","year":"2016","journal-title":"Drug Design, Development and Therapy"},{"key":"10.1016\/j.pharmthera.2019.107402_bb1905","doi-asserted-by":"crossref","DOI":"10.1126\/science.aaj2161","article-title":"Deconstructing behavioral neuropharmacology with cellular specificity","volume":"356","author":"Shields","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.pharmthera.2019.107402_bb1910","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/npp.2009.83","article-title":"The neurocircuitry of fear, stress, and anxiety disorders","volume":"35","author":"Shin","year":"2010","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pharmthera.2019.107402_bb1915","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1016\/j.celrep.2014.11.001","article-title":"Genetic disruption of 2-arachidonoylglycerol synthesis reveals a key role for endocannabinoid signaling in anxiety modulation","volume":"9","author":"Shonesy","year":"2014","journal-title":"Cell Reports"},{"key":"10.1016\/j.pharmthera.2019.107402_bb1920","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/164_2018_113","article-title":"Pharmacology of MDMA- and amphetamine-like new psychoactive substances","volume":"252","author":"Simmler","year":"2018","journal-title":"Handbook of Experimental Pharmacology"},{"key":"10.1016\/j.pharmthera.2019.107402_bb1925","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.neubiorev.2006.02.003","article-title":"Altered brain activity processing in high-anxiety rodents revealed by challenge paradigms and functional mapping","volume":"31","author":"Singewald","year":"2007","journal-title":"Neuroscience and Biobehavioral Reviews"},{"issue":"1","key":"10.1016\/j.pharmthera.2019.107402_bb1930","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s00213-018-5054-x","article-title":"Rodent models of impaired fear extinction","volume":"236","author":"Singewald","year":"2019","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pharmthera.2019.107402_bb1935","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.pharmthera.2014.12.004","article-title":"Pharmacology of cognitive enhancers for exposure-based therapy of fear, anxiety and trauma-related disorders","volume":"149","author":"Singewald","year":"2015","journal-title":"Pharmacology & Therapeutics"},{"issue":"10173","key":"10.1016\/j.pharmthera.2019.107402_bb1940","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/S0140-6736(18)31793-8","article-title":"Pharmacological treatments for generalised anxiety disorder: A systematic review and network meta-analysis","volume":"393","author":"Slee","year":"2019","journal-title":"Lancet."},{"key":"10.1016\/j.pharmthera.2019.107402_bb1945","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.ctcp.2018.09.003","article-title":"The effectiveness and safety of Kava Kava for treating anxiety symptoms: A systematic review and analysis of randomized clinical trials","volume":"33","author":"Smith","year":"2018","journal-title":"Complementary Therapies in Clinical Practice"},{"key":"10.1016\/j.pharmthera.2019.107402_bb1950","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1038\/npp.2015.266","article-title":"The genetics of stress-related disorders: PTSD, depression, and anxiety disorders","volume":"41","author":"Smoller","year":"2016","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pharmthera.2019.107402_bb1955","doi-asserted-by":"crossref","first-page":"291","DOI":"10.2174\/1570159X14666160509123955","article-title":"Evidences for the anti-panic actions of Cannabidiol","volume":"15","author":"Soares","year":"2017","journal-title":"Current Neuropharmacology"},{"key":"10.1016\/j.pharmthera.2019.107402_bb1960","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1007\/s00213-017-4556-2","article-title":"Don't stress about CRF: Assessing the translational failures of CRF1antagonists","volume":"234","author":"Spierling","year":"2017","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pharmthera.2019.107402_bb1965","series-title":"Advances in psychiatry","first-page":"33","article-title":"Anxiety disorders: From bench to bedside and beyond","author":"Starke","year":"2019"},{"key":"10.1016\/j.pharmthera.2019.107402_bb1970","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1177\/0269881115612236","article-title":"Propranolol for the treatment of anxiety disorders: Systematic review and meta-analysis","volume":"30","author":"Steenen","year":"2016","journal-title":"Journal of Psychopharmacology"},{"key":"10.1016\/j.pharmthera.2019.107402_bb1975","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1038\/mp.2016.217","article-title":"Pattern of structural brain changes in social anxiety disorder after cognitive behavioral group therapy: A longitudinal multimodal MRI study","volume":"22","author":"Steiger","year":"2017","journal-title":"Molecular Psychiatry"},{"key":"10.1016\/j.pharmthera.2019.107402_bb1980","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.4088\/JCP.11m07493","article-title":"Agomelatine prevents relapse in generalized anxiety disorder: A 6-month randomized, double-blind, placebo-controlled discontinuation study","volume":"73","author":"Stein","year":"2012","journal-title":"The Journal of Clinical Psychiatry"},{"key":"10.1016\/j.pharmthera.2019.107402_bb1985","doi-asserted-by":"crossref","first-page":"362","DOI":"10.4088\/JCP.13m08433","article-title":"Agomelatine in generalized anxiety disorder: An active comparator and placebo-controlled study","volume":"75","author":"Stein","year":"2014","journal-title":"The Journal of Clinical Psychiatry"},{"key":"10.1016\/j.pharmthera.2019.107402_bb1990","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/j.euroneuro.2018.05.006","article-title":"12-week double-blind randomized multicenter study of efficacy and safety of agomelatine (25-50mg\/day) versus escitalopram (10-20mg\/day) in out-patients with severe generalized anxiety disorder","volume":"28","author":"Stein","year":"2018","journal-title":"European Neuropsychopharmacology"},{"key":"10.1016\/j.pharmthera.2019.107402_bb1995","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1097\/ALN.0000000000002667","article-title":"Increased reactivity of the mesolimbic reward system after ketamine injection in patients with treatment-resistant major depressive disorder","volume":"130","author":"Sterpenich","year":"2019","journal-title":"Anesthesiology"},{"key":"10.1016\/j.pharmthera.2019.107402_bb2000","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1517\/17460441.2014.857309","article-title":"Anxiolytic drug discovery: What are the novel approaches and how can we improve them?","volume":"9","author":"Stewart","year":"2014","journal-title":"Expert Opinion on Drug Discovery"},{"key":"10.1016\/j.pharmthera.2019.107402_bb2005","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1517\/13543784.2015.1019063","article-title":"The failure of anxiolytic therapies in early clinical trials: What needs to be done","volume":"24","author":"Stewart","year":"2015","journal-title":"Expert Opinion on Investigational Drugs"},{"key":"10.1016\/j.pharmthera.2019.107402_bb2010","doi-asserted-by":"crossref","first-page":"281","DOI":"10.3389\/fnbeh.2018.00281","article-title":"Neuroscience informed prolonged exposure practice: Increasing efficiency and efficacy through mechanisms","volume":"12","author":"Stojek","year":"2018","journal-title":"Frontiers in Behavioral Neuroscience"},{"key":"10.1016\/j.pharmthera.2019.107402_bb2015","doi-asserted-by":"crossref","first-page":"18144","DOI":"10.1073\/pnas.1208852109","article-title":"Oxytocin facilitates protective responses to aversive social stimuli in males","volume":"109","author":"Striepens","year":"2012","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.pharmthera.2019.107402_bb2020","first-page":"611","article-title":"The diagnosis and treatment of anxiety disorders","volume":"155","author":"Strohle","year":"2018","journal-title":"Deutsches \u00c4rzteblatt International"},{"key":"10.1016\/j.pharmthera.2019.107402_bb2025","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1093\/ijnp\/pyy048","article-title":"Suicidal ideation and suicidal behavior as rare adverse events of antidepressant medication: Current report from the AMSP multicenter drug safety surveillance project","volume":"21","author":"Stubner","year":"2018","journal-title":"The International Journal of Neuropsychopharmacology"},{"key":"10.1016\/j.pharmthera.2019.107402_bb2030","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1080\/14656566.2018.1549542","article-title":"Evaluation of vilazodone for the treatment of depressive and anxiety disorders","volume":"20","author":"Stuivenga","year":"2019","journal-title":"Expert Opinion on Pharmacotherapy"},{"key":"10.1016\/j.pharmthera.2019.107402_bb2035","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1016\/j.neuropharm.2012.02.012","article-title":"Riluzole produces distinct anxiolytic-like effects in rats without the adverse effects associated with benzodiazepines","volume":"62","author":"Sugiyama","year":"2012","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pharmthera.2019.107402_bb2040","first-page":"S10","article-title":"Time since trauma in PTSD: Phase 3 multi-center, double-blind, placebo-controlled trial of TNX-102 SL, a sublingual formualtion of cyclopbenzaprine, in military-RElated PTSD (study TNX-CY-P301)","volume":"15","author":"Sullivan","year":"2018","journal-title":"Innoations in Clincial Neuroscience"},{"key":"10.1016\/j.pharmthera.2019.107402_bb2045","author":"Takeda"},{"issue":"Suppl. 3","key":"10.1016\/j.pharmthera.2019.107402_bb2050","doi-asserted-by":"crossref","first-page":"S482","DOI":"10.1016\/j.euroneuro.2012.06.016","article-title":"Synergistic mechanisms involved in the antidepressant effects of agomelatine","volume":"22","author":"Tardito","year":"2012","journal-title":"European Neuropsychopharmacology"},{"key":"10.1016\/j.pharmthera.2019.107402_bb2055","series-title":"Charney & Nestler's neurobiology of mental illness","first-page":"451","article-title":"Animal models and assays probing anxiety-related behaviors and neural circuits","author":"Tasan","year":"2018"},{"key":"10.1016\/j.pharmthera.2019.107402_bb2060","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/npp.2017.194","article-title":"Ketamine for social anxiety disorder: A randomized, placebo-controlled crossover trial","volume":"43","author":"Taylor","year":"2018","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pharmthera.2019.107402_bb2065","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s11920-015-0586-9","article-title":"Neuroimaging and anxiety: The neural substrates of pathological and non-pathological anxiety","volume":"17","author":"Taylor","year":"2015","journal-title":"Current Psychiatry Reports"},{"key":"10.1016\/j.pharmthera.2019.107402_bb2070","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.janxdis.2012.02.010","article-title":"Non-adherence and non-response in the treatment of anxiety disorders","volume":"26","author":"Taylor","year":"2012","journal-title":"Journal of Anxiety Disorders"},{"key":"10.1016\/j.pharmthera.2019.107402_bb2075","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1097\/YIC.0000000000000045","article-title":"Efficacy of vilazodone on anxiety symptoms in patients with major depressive disorder","volume":"29","author":"Thase","year":"2014","journal-title":"International Clinical Psychopharmacology"},{"key":"10.1016\/j.pharmthera.2019.107402_bb2080","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1097\/YIC.0000000000000180","article-title":"Effects of vilazodone on suicidal ideation and behavior in adults with major depressive disorder or generalized anxiety disorder: Post-hoc analysis of randomized, double-blind, placebo-controlled trials","volume":"32","author":"Thase","year":"2017","journal-title":"International Clinical Psychopharmacology"},{"key":"10.1016\/j.pharmthera.2019.107402_bb2085","author":"The Scientist"},{"key":"10.1016\/j.pharmthera.2019.107402_bb2090","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.psc.2017.08.007","article-title":"Can cognitive behavioral therapy for anxiety and depression be improved with pharmacotherapy? A meta-analysis","volume":"40","author":"Tolin","year":"2017","journal-title":"The Psychiatric Clinics of North America"},{"key":"10.1016\/j.pharmthera.2019.107402_bb2095","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/nrn3945","article-title":"Neuronal circuits for fear and anxiety","volume":"16","author":"Tovote","year":"2015","journal-title":"Nature Reviews. Neuroscience"},{"key":"10.1016\/j.pharmthera.2019.107402_bb2100","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1038\/mp.2014.122","article-title":"Epigenetic modulation of chronic anxiety and pain by histone deacetylation","volume":"20","author":"Tran","year":"2015","journal-title":"Molecular Psychiatry"},{"key":"10.1016\/j.pharmthera.2019.107402_bb2105","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.tins.2011.10.003","article-title":"Fear conditioning and extinction: Emotional states encoded by distinct signaling pathways","volume":"35","author":"Tronson","year":"2012","journal-title":"Trends in Neurosciences"},{"key":"10.1016\/j.pharmthera.2019.107402_bb2110","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1523\/JNEUROSCI.0352-18.2018","article-title":"Loss of adult 5-HT1A autoreceptors results in a paradoxical Anxiogenic response to antidepressant treatment","volume":"39","author":"Turcotte-Cardin","year":"2019","journal-title":"The Journal of Neuroscience"},{"key":"10.1016\/j.pharmthera.2019.107402_bb2115","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1002\/da.22664","article-title":"Is cannabis treatment for anxiety, mood, and related disorders ready for prime time?","volume":"34","author":"Turna","year":"2017","journal-title":"Depression and Anxiety"},{"key":"10.1016\/j.pharmthera.2019.107402_bb2120","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/S0006-3223(03)00412-8","article-title":"Immediate treatment with propranolol decreases posttraumatic stress disorder two months after trauma","volume":"54","author":"Vaiva","year":"2003","journal-title":"Biological Psychiatry"},{"key":"10.1016\/j.pharmthera.2019.107402_bb2125","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/7854_2017_34","article-title":"Subanesthetic dose ketamine in posttraumatic stress disorder: A role for reconsolidation during trauma-focused psychotherapy?","volume":"38","author":"Veen","year":"2018","journal-title":"Current Topics in Behavioral Neurosciences"},{"key":"10.1016\/j.pharmthera.2019.107402_bb2130","doi-asserted-by":"crossref","first-page":"3473","DOI":"10.1007\/s00213-016-4396-5","article-title":"The effects of ecstasy on neurotransmitter systems: A review on the findings of molecular imaging studies","volume":"233","author":"Vegting","year":"2016","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pharmthera.2019.107402_bb2135","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1055\/s-2007-979474","article-title":"Kava-kava extract WS 1490 versus placebo in anxiety disorders--a randomized placebo-controlled 25-week outpatient trial","volume":"30","author":"Volz","year":"1997","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.pharmthera.2019.107402_bb2140","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1021\/acschemneuro.6b00029","article-title":"Central nervous system multiparameter optimization desirability: Application in drug discovery","volume":"7","author":"Wager","year":"2016","journal-title":"ACS Chemical Neuroscience"},{"key":"10.1016\/j.pharmthera.2019.107402_bb2145","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1523\/JNEUROSCI.22-06-02343.2002","article-title":"Facilitation of conditioned fear extinction by systemic administration or intra-amygdala infusions of D-cycloserine as assessed with fear-potentiated startle in rats","volume":"22","author":"Walker","year":"2002","journal-title":"The Journal of Neuroscience"},{"key":"10.1016\/j.pharmthera.2019.107402_bb2150","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1007\/s00213-018-4983-8","article-title":"Modulation of naturalistic maladaptive memories using behavioural and pharmacological reconsolidation-interfering strategies: A systematic review and meta-analysis of clinical and 'sub-clinical' studies","volume":"235","author":"Walsh","year":"2018","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pharmthera.2019.107402_bb2155","doi-asserted-by":"crossref","first-page":"695","DOI":"10.3389\/fgene.2018.00695","article-title":"Crosstalk of genetic variants, allele-specific DNA methylation, and environmental factors for complex disease risk","volume":"9","author":"Wang","year":"2019","journal-title":"Frontiers in Genetics"},{"key":"10.1016\/j.pharmthera.2019.107402_bb2160","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.cpr.2017.10.010","article-title":"Exposure therapy augmentation: A review and extension of techniques informed by an inhibitory learning approach","volume":"59","author":"Weisman","year":"2018","journal-title":"Clinical Psychology Review"},{"issue":"11","key":"10.1016\/j.pharmthera.2019.107402_bb2165","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1002\/jcph.1263","article-title":"The pharmacology, pharmacokinetics, efficacy, and adverse events associated with kava","volume":"58","author":"White","year":"2018","journal-title":"Journal of Clinical Pharmacology"},{"key":"10.1016\/j.pharmthera.2019.107402_bb2170","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1001\/jama.2015.6358","article-title":"Cannabinoids for medical use: A systematic review and meta-analysis","volume":"313","author":"Whiting","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.pharmthera.2019.107402_bb2175","doi-asserted-by":"crossref","DOI":"10.1038\/tp.2016.231","article-title":"Enhancing dopaminergic signaling and histone acetylation promotes long-term rescue of deficient fear extinction","volume":"6","author":"Whittle","year":"2016","journal-title":"Translational Psychiatry"},{"key":"10.1016\/j.pharmthera.2019.107402_bb2180","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1042\/BST20130233","article-title":"HDAC inhibitors as cognitive enhancers in fear, anxiety and trauma therapy: Where do we stand?","volume":"42","author":"Whittle","year":"2014","journal-title":"Biochemical Society Transactions"},{"key":"10.1016\/j.pharmthera.2019.107402_bb2185","doi-asserted-by":"crossref","first-page":"538","DOI":"10.4140\/TCP.n.2013.538","article-title":"The history of benzodiazepines","volume":"28","author":"Wick","year":"2013","journal-title":"The Consultant Pharmacist"},{"key":"10.1016\/j.pharmthera.2019.107402_bb2190","series-title":"Anxiety disorders: Translational perspectives on diagnosis and treatment","first-page":"389","article-title":"Stress, anxiety and depression and the role of glutamate neurotransmission","author":"Williams","year":"2015"},{"key":"10.1016\/j.pharmthera.2019.107402_bb2195","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.mri.2007.03.016","article-title":"The anxiolytic effects of midazolam during anticipation to pain revealed using fMRI","volume":"25","author":"Wise","year":"2007","journal-title":"Magnetic Resonance Imaging"},{"key":"10.1016\/j.pharmthera.2019.107402_bb2200","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.euroneuro.2005.04.012","article-title":"Size and burden of mental disorders in Europe--a critical review and appraisal of 27 studies","volume":"15","author":"Wittchen","year":"2005","journal-title":"European Neuropsychopharmacology"},{"key":"10.1016\/j.pharmthera.2019.107402_bb2205","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1093\/biostatistics\/kxx069","article-title":"Estimation of clinical trial success rates and related parameters","volume":"20","author":"Wong","year":"2019","journal-title":"Biostatistics"},{"key":"10.1016\/j.pharmthera.2019.107402_bb2210","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/nn.4478","article-title":"Building better biomarkers: Brain models in translational neuroimaging","volume":"20","author":"Woo","year":"2017","journal-title":"Nature Neuroscience"},{"key":"10.1016\/j.pharmthera.2019.107402_bb2215","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.psychres.2014.09.005","article-title":"Pharmacological blockade of memory reconsolidation in posttraumatic stress disorder: Three negative psychophysiological studies","volume":"225","author":"Wood","year":"2015","journal-title":"Psychiatry Research"},{"key":"10.1016\/j.pharmthera.2019.107402_bb2220","doi-asserted-by":"crossref","first-page":"4923","DOI":"10.1113\/JP276431","article-title":"Short-chain fatty acids: Microbial metabolites that alleviate stress-induced brain-gut axis alterations","volume":"596","author":"van de Wouw","year":"2018","journal-title":"The Journal of Physiology"},{"key":"10.1016\/j.pharmthera.2019.107402_bb2225","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1517\/14728222.2011.628314","article-title":"Central functions of neuropeptide Y in mood and anxiety disorders","volume":"15","author":"Wu","year":"2011","journal-title":"Expert Opinion on Therapeutic Targets"},{"key":"10.1016\/j.pharmthera.2019.107402_bb2230","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.neubiorev.2018.11.005","article-title":"Anxious brain networks: A coordinate-based activation likelihood estimation meta-analysis of resting-state functional connectivity studies in anxiety","volume":"96","author":"Xu","year":"2019","journal-title":"Neuroscience and Biobehavioral Reviews"},{"issue":"1","key":"10.1016\/j.pharmthera.2019.107402_bb2235","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/0269881118817384","article-title":"Serotonin actions within the prelimbic cortex induce anxiolysis mediated by serotonin 1a receptors","volume":"33","author":"Yamashita","year":"2019","journal-title":"Journal of Psychopharmacology"},{"key":"10.1016\/j.pharmthera.2019.107402_bb2240","doi-asserted-by":"crossref","DOI":"10.1136\/gpsych-2019-100056","article-title":"Effects of regulating intestinal microbiota on anxiety symptoms: A systematic review","volume":"32","author":"Yang","year":"2019","journal-title":"General Psychiatry"},{"key":"10.1016\/j.pharmthera.2019.107402_bb2245","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.neuroimage.2017.12.011","article-title":"Network analysis reveals disrupted functional brain circuitry in drug-naive social anxiety disorder","volume":"190","author":"Yang","year":"2019","journal-title":"Neuroimage"},{"key":"10.1016\/j.pharmthera.2019.107402_bb2250","doi-asserted-by":"crossref","first-page":"S84","DOI":"10.1016\/S0924-977X(10)70098-5","article-title":"Intranasal oxytocin in patients with post traumatic stress disorder: A single dose, pilot double blind crossover study","volume":"20","author":"Yazker","year":"2010","journal-title":"European Neuropsychopharmacology"},{"key":"10.1016\/j.pharmthera.2019.107402_bb2255","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.2174\/1389450118666171117131151","article-title":"Vortioxetine treatment for anxiety disorder: A meta-analysis study","volume":"19","author":"Yee","year":"2018","journal-title":"Current Drug Targets"},{"key":"10.1016\/j.pharmthera.2019.107402_bb2260","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1021\/acschemneuro.7b00040","article-title":"Role of academic drug discovery in the quest for new CNS therapeutics","volume":"8","author":"Yokley","year":"2017","journal-title":"ACS Chemical Neuroscience"},{"key":"10.1016\/j.pharmthera.2019.107402_bb2265","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.cobeha.2018.03.001","article-title":"Survival circuits in affective disorders","volume":"24","author":"Young","year":"2018","journal-title":"Current Opinion in Behavioral Sciences"},{"key":"10.1016\/j.pharmthera.2019.107402_bb2270","doi-asserted-by":"crossref","first-page":"e634","DOI":"10.1038\/tp.2015.138","article-title":"3,4-Methylenedioxymethamphetamine facilitates fear extinction learning","volume":"5","author":"Young","year":"2015","journal-title":"Translation Psychiatry"},{"key":"10.1016\/j.pharmthera.2019.107402_bb2275","doi-asserted-by":"crossref","first-page":"2883","DOI":"10.1007\/s00213-017-4684-8","article-title":"Inhibition of serotonin transporters disrupts the enhancement of fear memory extinction by 3,4-methylenedioxymethamphetamine (MDMA)","volume":"234","author":"Young","year":"2017","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.pharmthera.2019.107402_bb2280","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.biopsych.2012.10.019","article-title":"A randomized trial of a low-trapping nonselective N-methyl-D-aspartate channel blocker in major depression","volume":"74","author":"Zarate","year":"2013","journal-title":"Biological Psychiatry"},{"key":"10.1016\/j.pharmthera.2019.107402_bb2285","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.ajp.2017.01.016","article-title":"Efficacy and tolerability of vilazodone for the acute treatment of generalized anxiety disorder: A meta-analysis","volume":"26","author":"Zareifopoulos","year":"2017","journal-title":"Asian Journal of Psychiatry"},{"issue":"4","key":"10.1016\/j.pharmthera.2019.107402_bb2290","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1007\/s00213-018-5124-0","article-title":"Activation of somatodendritic 5-HT1A autoreceptors reduces the acquisition and expression of cued fear in the rat fear-potentiated startle test","volume":"236","author":"Zhao","year":"2019","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pharmthera.2019.107402_bb2295","doi-asserted-by":"crossref","first-page":"113","DOI":"10.3390\/ph7020113","article-title":"From single target to multitarget\/network therapeutics in Alzheimer's therapy","volume":"7","author":"Zheng","year":"2014","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.pharmthera.2019.107402_bb2300","doi-asserted-by":"crossref","first-page":"80","DOI":"10.5492\/wjccm.v1.i3.80","article-title":"General anesthesia mediated by effects on ion channels","volume":"1","author":"Zhou","year":"2012","journal-title":"World Journal of Critical Care Medicine"},{"key":"10.1016\/j.pharmthera.2019.107402_bb2305","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1007\/s00115-018-0625-y","article-title":"Patho- and therapyepigenetics of mental disorders","volume":"89","author":"Ziegler","year":"2018","journal-title":"Nervenarzt"},{"key":"10.1016\/j.pharmthera.2019.107402_bb2310","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.lfs.2018.08.050","article-title":"Serotonin receptors in depression and anxiety: Insights from animal studies","volume":"210","author":"Zmudzka","year":"2018","journal-title":"Life Sciences"},{"key":"10.1016\/j.pharmthera.2019.107402_bb2315","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.drudis.2010.02.011","article-title":"Progress in corticotropin-releasing factor-1 antagonist development","volume":"15","author":"Zorrilla","year":"2010","journal-title":"Drug Discovery Today"},{"key":"10.1016\/j.pharmthera.2019.107402_bb2320","doi-asserted-by":"crossref","first-page":"11158","DOI":"10.1523\/JNEUROSCI.1547-16.2016","article-title":"Ketamine: NMDA receptors and beyond","volume":"36","author":"Zorumski","year":"2016","journal-title":"The Journal of Neuroscience"},{"key":"10.1016\/j.pharmthera.2019.107402_bb2325","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/j.biopsych.2016.11.012","article-title":"Intranasal oxytocin to prevent posttraumatic stress disorder symptoms: A randomized controlled trial in emergency department patients","volume":"81","author":"van Zuiden","year":"2017","journal-title":"Biological Psychiatry"},{"key":"10.1016\/j.pharmthera.2019.107402_bb2330","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.jpsychires.2005.09.005","article-title":"Lifetime associations between cannabis, use, abuse, and dependence and panic attacks in a representative sample","volume":"40","author":"Zvolensky","year":"2006","journal-title":"Journal of Psychiatric Research"}],"container-title":["Pharmacology & Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725819301512?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725819301512?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T11:02:05Z","timestamp":1778670125000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163725819301512"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":466,"alternative-id":["S0163725819301512"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmthera.2019.107402","relation":{},"ISSN":["0163-7258"],"issn-type":[{"value":"0163-7258","type":"print"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel pharmacological targets in drug development for the treatment of anxiety and anxiety-related disorders","name":"articletitle","label":"Article Title"},{"value":"Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharmthera.2019.107402","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"107402"}}